

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Palliative Care

Version Preliminary 1.2014

NCCN.org

Continue



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2014 Panel Members

Palliative Care

[NCCN Guidelines Index](#)
[Palliative Care TOC](#)
[Discussion](#)

* **Michael H. Levy, MD, PhD/Chair † £**
Fox Chase Cancer Center

* **Thomas Smith, MD/Vice-Chair**
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins

Amy Alvarez-Perez, MD
Roswell Park Cancer Institute

Anthony Back, MD † £
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance

Justin N. Baker, MD €
St. Jude Children`s Research Hospital/
The University of Tennessee
Health Science Center

Susan Block, MD £ θ
Dana-Farber Cancer Institute

Shirley N. Codada, MD £ ρ
Moffitt Cancer Center

Shalini Dalal, MD £
The University of Texas
MD Anderson Cancer Center

NCCN
Mary Anne Bergman
Jillian Scavone, PhD

Maria Dans, MD £
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

Jean S. Kutner, MD
University of Colorado Cancer Center

Elizabeth Kvale, MD £
University of Alabama at Birmingham
Comprehensive Cancer Center

Sumathi Misra, MD ρ £ ρ
Vanderbilt-Ingram Cancer Center

William Mitchell, MD
UC San Diego Moores Cancer Center

Todd M. Sauer, MD £
Fred & Pamela Buffett Cancer Center at
The Nebraska Medical Center

David Spiegel, MD θ
Stanford Cancer Institute

Linda Sutton, MD † £
Duke Cancer Institute

Robert M. Taylor, MD £ Ψ
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Jennifer Temel, MD † £
Massachusetts General Hospital
Cancer Center

Roma Tickoo, MD, MPH ρ £
Memorial Sloan-Kettering Cancer Center

Susan G. Urba, MD † £
University of Michigan
Comprehensive Cancer Center

Carin Van Zyl, MD £
City of Hope Comprehensive Cancer Center

Sharon M. Weinstein, MD £ Ψ
Huntsman Cancer Institute
at the University of Utah

‡ Hematology/Hematology oncology
† Medical oncology
ρ Internal medicine
£ Supportive care including palliative
and pain management
θ Psychiatry and psychology, including
health behavior
Ψ Neurology/Neuro-oncology
φ Anesthesiology
ρ Geriatric medicine
€ Pediatric oncology
* Writing committee member

[NCCN Guidelines Panel Disclosures](#)

Continue

[NCCN Palliative Care Panel Members](#)
[Summary of the Guidelines Updates](#)

[Definition and Standards of Palliative Care \(PAL-1\)](#)

[Palliative Care Overview \(PAL-2\)](#)

[Screening and Assessment by Oncology Team \(PAL-3\)](#)

[Criteria for Consultation with Palliative Care Specialist \(PAL-6\)](#)

[Oncology Team Interventions and Reassessment \(PAL-8\)](#)

[Benefits/Risks of Anticancer Therapy \(PAL-9\)](#)

[Symptoms: Pain \(PAL-10\)](#)

[Symptoms: Dyspnea \(PAL-11\)](#)

[Symptoms: Anorexia/Cachexia \(PAL-13\)](#)

[Symptoms: Nausea and Vomiting \(PAL-15\)](#)

[Symptoms: Constipation \(PAL-17\)](#)

[Symptoms: Malignant Bowel Obstruction \(PAL-18\)](#)

[Symptoms: Sleep/Wake Disturbances Including Insomnia and Sedation \(PAL-20\)](#)

[Symptoms: Delirium \(PAL-21\)](#)

[Social Support/Resource Management \(PAL-23\)](#)

[Goals and Expectations, Educational and Informational Needs, and Cultural Factors Affecting Care for the Patient and Family \(PAL-25\)](#)

[Advance Care Planning \(PAL-27\)](#)

[Response to Requests for Hastened Death \(PAL-29\)](#)

[Care of the Imminently Dying Patient \(PAL-30\)](#)

[Palliative Sedation \(PAL-31\)](#)

[After-Death Interventions \(PAL-32\)](#)

Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical_trials/physician.html](#).

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#)

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2014.

**Updates in Version 1.2014 of the NCCN Guidelines for Palliative Care from Version 2.2013 include:****[PAL-1](#)**

- Under Standards of Palliative Care, 5th bullet modified to include *social workers, chaplains, and pharmacists*

[PAL-2](#)

- Bottom branch, 1st sub-bullet modified as follows: ~~Discuss~~ Anticipate symptoms and discuss preventative *measures* (Also for PAL-3)
- *Interventions* has replaced *efforts* throughout the guidelines

[PAL-3](#)

- Under Life Expectancy ≤ 6 mo, *Palliative stenting or venting gastrostomy* is new to the page (Also for PAL-6)

[PAL-4](#)

- 4th bullet modified: *Goals and meaning of anticancer therapy* ~~to~~ for patient and family
- *Confirm the patient's understanding of incurability of disease* is new to the page (Also for PAL-9)
- *"Look for opportunities to use single agents to treat multiple symptoms"* is a new footnote and corresponds to *Symptoms* (Also for PAL-5, corresponding to *Psychosocial/psychiatric*)

[PAL-6](#)

- 6th bullet modified: Complex ICU admissions (those *involving multi-organ system failure or prolonged mechanical ventilations*) ~~multiple complications or those requiring lengthy ventilator support~~
- Last bullet modified: ~~Inability~~ *Resistance* to engaging in advance care planning and care plan
- Deleted footnote "e" ~~Communication barriers include: language, literacy, and physical barriers~~ and instead included sub-bullets under "Communication barriers" to replace the footnote

[PAL-7](#)

- *Children under 18 years of age living in the household* is new to the page

[PAL-9](#)

- 8th bullet is new to the page: Reassess understanding of goals of therapy and prognosis

[PAL-9](#) (continued)

- 10th bullet modified: Redirect goals and hopes to those that are achievable *based upon likely prognosis and life expectancy*
- 12th bullet modified to: Consider ~~potential~~ discontinuation of anticancer treatment
- 13th bullet modified: ~~Encourage~~ Discontinue of anticancer therapy

[PAL-11](#)

- Under Interventions, 2nd bullet, 5th sub-bullet is new to the page: Anticoagulants for pulmonary emboli
 - ▶ Under "Relieve symptoms," 1st sub-bullet modified: Oxygen therapy for symptomatic hypoxia
 - ▶ 5th sub-bullet modified: If dyspnea *is not relieved by opioids* and is associated with anxiety....
 - ▶ 6th sub-bullet modified to include: ~~Temporary ventilatory~~ *Noninvasive Positive-Pressure Ventilation (NPPV)*....

[PAL-12](#)

- 5th bullet, 1st sub-bullet, modified: Address patient and family preferences, prognosis, and reversibility of *respiratory failure*

[PAL-15](#)

- 5th bullet, 1st sub-bullet: changed TID-QID to BID-TID
- 6th bullet, modified as follows: Gastric outlet obstruction (~~squashed stomach syndrome~~) from intra-abdominal tumor or liver metastasis
 - ▶ 1st sub-bullet modified as follows: If not contraindicated by comorbid conditions, treat with corticosteroids, a proton pump inhibitor, and metoclopramide ~~and consider~~
 - ▶ 2nd sub-bullet now includes Endoscopic stenting
 - ▶ 3rd sub-bullet is new to the page: Decompressing G-Tube
- 7th bullet modified: Treat metabolic abnormalities
 - ▶ In the 1st sub-bullet, modified: ~~Correct~~ Hypercalcemia
 - ▶ 2nd sub-bullet, modified: ~~Treat~~ Uremia
- 8th bullet is new to the page: *Gastritis/GERD*
 - ▶ *Proton pump inhibitor*
 - ▶ *H2-blocker*

PAL-16

- Under Interventions, *olanzapine* is new to the page and it reads as follows: *Titrate dopamine receptor antagonist (eg, prochlorperazine, haloperidol, metoclopramide, olanzapine) to maximum benefit and tolerance*
 - Under “If NV Persists, *olanzapine* was added as follows: *Add a corticosteroid (eg, dexamethasone) ± olanzapine, if not already tried*

PAL-17

- Under Interventions, 10th bullet, modified as follows: *Consider methylnaltrexone for opioid-induced constipation, except for post-op ileus and mechanical bowel obstruction, 0.15 mg/kg SC every other day, no more than once a day*

PAL-18

- The word *may* was added to footnote “m” and reads as follows: *Plain film radiography may be helpful in confirming the clinical diagnosis of bowel obstruction. Consider a computed tomography scan if surgical intervention is contemplated, as it is more sensitive and may help identify the cause of obstruction*

PAL-19

- 3rd bullet, 1st sub-bullet, modified as follows: *Ultrasound-guided gastrostomy tube for drainage* ~~venting tube~~
- 4th bullet now reads: *Pharmacologic management when the goal is maintaining gut function*
 - 2nd sub-bullet has been removed: ~~Consider as an adjunct to an invasive procedure when invasive procedures are not an option~~
- 5th bullet, *Pharmacologic management when gut function cannot be maintained* is new to the page
 - 2nd sub-bullet, ~~Consider early in the diagnosis due to high efficacy and tolerability~~ has been removed
- Footnote “o” has been modified, *Risk factors for poor surgical outcome* ~~prognosis criteria for surgery~~ include: *ascites, carcinomatosis, palpable intraabdominal masses, multiple bowel obstructions, previous abdominal radiation, very advanced disease, and poor overall clinical status*

PAL-20

- Under Interventions, 7th bullet, 1st sub-bullet, 3rd sub-sub-bullet *Zolpidem* has changed from *5-10 mg PO at bedtime* to *5 mg*
 - 5th sub-sub-bullet is new to the page, *Olanzapine, 2.5-5 mg PO at bedtime*
 - 2nd sub-bullet, 2nd sub-sub-bullet, *second dose no later than 2:00PM* has been modified to *6 hours before bedtime*
 - 3rd sub-sub-bullet, *second dose no later than 2:00PM* has been modified to *12 hours before bedtime*

PAL-21

- Two sub-bullets under *Assess for delirium (eg, DSM-IV-criteria)* are new to the page and are as follows:
 - *Hyperactive*
 - *Hypoactive*
- 2nd bullet, 2nd sub-bullet is new to the page: *Unrelieved pain*
- Interventions, 1st bullet has been modified, ~~*Avoid benzodiazepines*~~ *Reduce or eliminate delirium-inducing medications as possible (eg, steroids, anticholinergics, and benzodiazepines)*

PAL-26

- Interventions, 6th bullet, *Respect goals and needs of the patient and family regarding the dying process* is new to the page
- 7th bullet has been modified: *Promote that patient does not die alone unless dying alone is an established preference of patient*

PAL-27

- Under Interventions: ~~Encourage designation of~~ *Ask patient if he/she has a living will, medical power of attorney, health care proxy, or patient surrogate for health care*
 - *If not, encourage patient to prepare one*

PAL-29

- *Vermont* was added to the list of states where Physician-assisted suicide is legal

MS-1

- The discussion section was updated to reflect the changes in the algorithm



DEFINITION OF PALLIATIVE CARE^a

Palliative care is a special kind of patient- and family-centered health care that focuses on effective management of pain and other distressing symptoms, while incorporating psychosocial and spiritual care according to patient/family needs, values, beliefs, and cultures. The goal of palliative care is to anticipate, prevent, and reduce suffering and to support the best possible quality of life for patients and their families, regardless of the stage of the disease or the need for other therapies. Palliative care begins at diagnosis and should be delivered concurrently with disease-directed, life-prolonging therapies and should facilitate patient autonomy, access to information, and choice. Palliative care becomes the main focus of care when disease-directed, life-prolonging therapies are no longer effective, appropriate, or desired. Palliative care should be initiated by the primary oncology team and then augmented by collaboration with an interdisciplinary team of palliative care experts.

STANDARDS OF PALLIATIVE CARE^b

- Institutions should develop processes for integrating palliative care into cancer care, both as part of usual oncology care and for patients with specialty palliative care needs.
- All cancer patients should be screened for palliative care needs at their initial visit, at appropriate intervals, and as clinically indicated.
- Patients and families should be informed that palliative care is an integral part of their comprehensive cancer care.
- Educational programs should be provided to all health care professionals and trainees so that they can develop effective palliative care knowledge, skills, and attitudes.
- Palliative care specialists and interdisciplinary palliative care teams, including board-certified palliative care physicians, advanced practice nurses, physician assistants, social workers, chaplains, and pharmacists, should be readily available to provide consultative or direct care to patients/families who request or require their expertise.
- Quality of palliative care should be monitored by institutional quality improvement programs.

^aHui D, Mori M, Parsons HA, et al. The lack of standard definitions in supportive and palliative oncology literature. *J Pain Symptom Manage* 2012;43:582-592.

^bFerris FD, Bruera E, Cherny N, et al. Palliative cancer care a decade later: accomplishments, the need, next steps – from the American Society of Clinical Oncology. *J Clin Oncol* 2009;27:3052-3058.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.


SCREENING^{c,d}

ASSESSMENT^{c,d}

PALLIATIVE CARE INTERVENTIONS^d

REASSESSMENT

AFTER-DEATH INTERVENTIONS



^cManagement of any patient with positive screening requires a care plan developed by an interdisciplinary team of physicians, nurses, social workers, and other mental health professionals, chaplains, nurse practitioners, physician assistants, and dietitians.

^dOncologists should integrate palliative care into general oncology care. Early consultation/collaboration with a palliative care specialist/hospice team should be considered to improve quality of life and survival.


Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**Assessment by
Oncology Team
(PAL-3)**

SCREENING^{c,d}

- Uncontrolled symptoms
or
- Moderate-to-severe distress related to cancer diagnosis and/or cancer therapy
or
- Serious comorbid physical, psychiatric, and psychosocial conditions
or
- Life expectancy ≤ 6 mo
 - Indicators include:
 - ◊ Metastatic solid tumors
 - ◊ Many stage IV cancers
 - ◊ Poor performance status
ECOG ≥ 3 or KPS ≤ 50
 - ◊ Hypercalcemia
 - ◊ Brain or cerebrospinal fluid metastasis
 - ◊ Delirium
 - ◊ Superior vena cava syndrome
 - ◊ Spinal cord compression
 - ◊ Cachexia
 - ◊ Malignant effusions
 - ◊ Palliative stenting or venting gastrostomy
- or
- Patient/family concerns about course of disease and decision-making
or
- Patient/family requests for palliative care

ASSESSMENT BY ONCOLOGY TEAM



^cManagement of any patient with positive screening requires a care plan developed by an interdisciplinary team of physicians, nurses, social workers, and other mental health professionals, chaplains, nurse practitioners, physician assistants, and dietitians.

^dOncologists should integrate palliative care into general oncology care. Early consultation/collaboration with a palliative care specialist/hospice team should be considered to improve quality of life and survival.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



ASSESSMENT BY ONCOLOGY TEAM

Benefits/risks of anticancer therapy

- Natural history of specific tumor
- Potential for response to further treatment
- Potential for treatment-related toxicities
- Goals and meaning of anticancer therapy for patient and family
- Impairment of vital organs
- Performance status
- Serious comorbid conditions
- Confirm the patient's understanding of incurability of disease

[Anticancer therapy interventions \(See PAL-9\)](#)

Personal goals/expectations

- Patient goals and expectations
 - ▶ Advance care planning
- Family goals and expectations
- Priorities for palliative care
 - ▶ Goals and meaning of anticancer therapy
 - ▶ Quality of life
- Eligibility for hospice, with needs that might be met by hospice

[Interventions \(See PAL-25\)](#)
[Advance Care Planning \(See PAL-27\)](#)

Symptoms^e


- Pain → [Pain Interventions \(See PAL-10\)](#)
- Dyspnea → [Dyspnea Interventions \(See PAL-11\)](#)
- Anorexia/cachexia → [Anorexia/Cachexia Interventions \(See PAL-13\)](#)
- Nausea/vomiting (NV) → [Nausea/Vomiting Interventions \(See PAL-15\)](#)
- Constipation → [Constipation Interventions \(See PAL-17\)](#)
- Malignant bowel obstruction → [Malignant Bowel Obstruction \(See PAL-18\)](#)
- Fatigue/weakness/asthenia → [See NCCN Cancer-Related Fatigue Guidelines](#)
- Insomnia/sedation → [Insomnia/Sedation Interventions \(See PAL-20\)](#)
- Delirium → [Delirium Interventions \(See PAL-21\)](#)

^eLook for opportunities to use single agents to treat multiple symptoms.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PALLIATIVE CARE ASSESSMENT



^eLook for opportunities to use single agents to treat multiple symptoms.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

CRITERIA FOR CONSULTATION WITH PALLIATIVE CARE SPECIALIST ASSESSMENT

Patient
characteristics

- Limited treatment options
- High risk of poor pain control or pain that remains resistant to conventional interventions, eg:
 - ▶ Neuropathic pain
 - ▶ Incident or breakthrough pain
 - ▶ Associated psychosocial and family distress
 - ▶ Rapid escalation of opioid dose
 - ▶ Multiple drug “allergies” or a history of multiple adverse reactions to pain and symptom management interventions
 - ▶ History of drug or alcohol abuse
- Non-pain symptoms that are suboptimally controlled by conventional management, high symptom burden ([See PAL-4](#) for symptoms)
- Palliative stenting or venting gastrostomy
- Frequent ED visits or hospital readmissions
- Complex ICU admissions (those involving multi-organ system failure or prolonged mechanical ventilations)
- High distress score (>4) ([See NCCN Guidelines for Distress Management](#))
- Cognitive impairment
- Severe comorbid conditions
- Communication barriers
 - ▶ language
 - ▶ literacy
 - ▶ physical barriers
- Request for hastened death
- Resistance to engaging in advance care planning and care plan

→ [See
Oncology
Team
Interventions
\(PAL-8\)](#)

[Continued next page](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



CRITERIA FOR CONSULTATION WITH PALLIATIVE CARE SPECIALIST

ASSESSMENT

Social
circumstances
or
Anticipatory
bereavement
issues



- Family/caregiver limitations
- Inadequate social support
- Intensely dependent relationship(s)
- Financial limitations
- Limited access to care
- Family discord
- Patient's concerns regarding care of dependents
- Spiritual or existential crisis
- Unresolved or multiple prior losses
- Children under 18 years of age living in the household

Staff
issues



- Compassion fatigue
- Moral distress



[See
Oncology
Team
Interventions
\(PAL-8\)](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



ONCOLOGY TEAM INTERVENTIONS

REASSESSMENT

- Consult with palliative care specialist/team^{c,d}
- Collaborate with other health care professionals treating the patient
- Refer to appropriate health care professionals
 - Mental health and social services
 - Pastoral care
 - Health care interpreters
 - Others
- Mobilize community support
 - Religious
 - School
 - Community agencies
- Expedite referral to hospice services when appropriate

- Acceptable:**
- Patient satisfied with response to anticancer therapy
 - Adequate pain and symptom control
 - Reduction of patient/family distress
 - Acceptable sense of control
 - Relief of caregiver burden
 - Strengthened relationships
 - Optimized quality of life
 - Personal growth and enhanced meaning
 - Advance care planning in progress

Ongoing re-evaluation and communication between the patient and health care team

Unacceptable

- Intensify palliative care interventions
- Consult with a mental health professional to evaluate and treat undiagnosed psychiatric disorders, substance abuse, and inadequate coping methods
- [See NCCN Guidelines for Distress Management](#)

Ongoing reassessment

^cManagement of any patient with positive screening requires a care plan developed by an interdisciplinary team of physicians, nurses, social workers and other mental health professionals, chaplains, nurse practitioners, physician assistants, and dietitians.

^dOncologists should integrate palliative care into general oncology care. Early consultation/collaboration with a palliative care specialist/hospice team should be considered to improve quality of life and survival.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

BENEFITS/RISKS OF ANTICANCER THERAPY

**ESTIMATED
LIFE
EXPECTANCY**

Years
→
Year
to
months

INTERVENTIONS

- Discuss whether intent and goals of therapy are palliative or curative
- Review the, risks of anticancer therapy, including possible effects on quality of life
- Confirm the patient's understanding of incurability of disease
- Provide appropriate anticancer therapy as outlined in [NCCN disease-specific guidelines](#)
- Provide appropriate prevention and management of symptoms caused by anticancer therapy
- Provide appropriate palliative care
- Prepare patient psychologically for possible disease progression

Months
to
weeks

- Reassess understanding of goals of therapy and prognosis
- Offer best supportive care, including referral to palliative care or hospice
- Redirect goals and hopes to those that are achievable based upon likely prognosis and life expectancy
- Provide guidance regarding anticipated course of disease
- Consider discontinuation of anticancer treatment

Weeks
to
days
(Dying
patient)

- Discontinue anticancer therapy
- Intensify palliative care in preparation for death
- Provide guidance regarding anticipated dying process
- Focus on symptom control and comfort
- Foster patient participation in preparing loved ones
- Refer to palliative care/hospice team

REASSESSMENT

Acceptable:

- Adequate pain and symptom control
- Reduction of patient/family distress
- Acceptable sense of control
- Relief of caregiver burden
- Strengthened relationships
- Optimized quality of life
- Personal growth and enhanced meaning

Unacceptable


→ Continue
anticancer therapy
and palliative care

- Change or discontinue anticancer therapy
- Review patient hopes about and meaning of anticancer therapy
- Intensify palliative care interventions
- Review advance care planning
- Consult or refer to specialized palliative care services or hospice

→ Ongoing
reassessment


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^fFor acute progressive dyspnea, more aggressive titration may be required.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

DYSPNEA

ESTIMATED LIFE EXPECTANCY

Years
Year to months
Months to weeks

→ [See Interventions \(PAL-11\)](#)

INTERVENTIONS

- Assess symptom intensity
 - ▶ Use physical signs of distress as potential dyspnea in noncommunicative patients
- Focus on comfort
 - ▶ Continue to treat underlying condition as appropriate
- Relieve symptoms
 - ▶ Fans
 - ▶ Oxygen if hypoxic and/or subjective relief is reported
 - ▶ Nonpharmacologic therapies; educational, psychosocial, and emotional support ([See PAL-11](#))
- If fluid overload is a contributing factor
 - ▶ Decrease/discontinue enteral or parenteral fluid
 - ▶ Consider low-dose diuretics
 - ▶ If opioid naive, morphine, 2.5-10 mg PO q 4 hr prn, 1-3 mg IV q 1 hr prn^f
 - ▶ Benzodiazepines (if benzodiazepine naive, starting dose lorazepam, 0.5-1 mg PO q 1 hr prn)
 - ▶ Reduce excessive secretions⁹ with scopolamine, 0.4 mg SC q 4 hr prn; 1.5 mg patches, 1-6 patches q 3 d; atropine 1% ophthalmic solution 1-2 drops SL q 4 h pr; or glycopyrrolate 0.2-0.4 mg IV or SQ q 4 hr prn
- Withhold/withdraw/initiate time-limited trial of mechanical ventilation as indicated
 - ▶ Address patient and family preferences, prognosis, and reversibility of respiratory failure
 - ▶ Provide sedation as needed
- Provide anticipatory guidance for patient/family regarding dying or respiratory failure
- Provide emotional and spiritual support

REASSESSMENT

- Acceptable:**
- Adequate dyspnea and symptom control
 - Reduction of patient/family distress
 - Acceptable sense of control
 - Relief of caregiver burden
 - Strengthened relationships
 - Optimized quality of life
 - Personal growth and enhanced meaning

→ Continue to treat and monitor symptoms and quality of life to determine whether status warrants change in strategies

Unacceptable →

- Intensify palliative care interventions and consider a consultation with a palliative care specialist
- Consider sedation for intractable symptoms ([See PAL-31](#))

→ Ongoing reassessment

^fFor acute progressive dyspnea, more aggressive titration may be required.

⁹Hughes A, et al. Audit of three antimuscarinic drugs for managing retained secretions. Palliative Medicine. 2000; 14:221-222.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**ESTIMATED
LIFE
EXPECTANCY**

ANOREXIA/CACHEXIA

REASSESSMENT

INTERVENTIONS

- Evaluate rate/severity of weight loss
- Treat readily reversible cause of anorexia:
 - Early satiety
 - ◊ Metoclopramide
 - Symptoms that interfere with intake
 - ◊ Dysgeusia
 - ◊ Xerostomia
 - ◊ Oral-pharyngeal candidiasis
 - ◊ Mucositis
 - ◊ NV
 - ◊ Dyspnea
 - ◊ Depression/anorexia
(Mirtazapine 7.5-30 mg hs)
 - ◊ Constipation
 - ◊ Pain
 - ◊ Fatigue
 - ◊ Eating disorders/body image
- Review/modify medications that interfere with intake
- Evaluate for endocrine abnormalities:
 - Hypogonadism
 - Thyroid dysfunction
 - Metabolic abnormalities (eg, increased calcium)
- Consider appetite stimulant
 - Megestrol acetate, 400-800 mg/d
 - Prednisone 10-20 mg BID^h
- Consider an exercise program
- Assess social and economic factors
- Consider nutrition consult
- Consider nutrition support, enteral and parenteral feedingⁱ (as appropriate)

- Acceptable:**
- Weight stabilization or gain
 - Improvement in symptoms that interfere with intake
 - Improved energy
 - Resolution of metabolic or endocrine abnormalities

Continue to treat and monitor symptoms and quality of life to determine whether status warrants change in strategies

Unacceptable

- Intensify palliative care interventions
- Provide dietary consultation
- Consider clinical trial

Ongoing reassessment

Years

Year to months

Months to weeks

Weeks to days
(Dying patient)

→ [See Interventions \(PAL-14\)](#)

^hDy S, Lorenz K, et al. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. 2008 J Clin Oncol 26:3886-3895.

ⁱAugust DA, Huhmann MB. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) JPEN J Parenter Enteral Nutr 2009 Sep-Oct;33(5):472-500.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**ESTIMATED
LIFE
EXPECTANCY**
Years →
Year to
months

ANOREXIA/CACHEXIA

INTERVENTIONS

[See Interventions \(PAL-13\)](#)

- Assess importance of symptoms of anorexia and cachexia to patient and family
- If important, consider appetite stimulant
 - ▶ Megestrol acetate, 400-800 mg/d
 - ▶ Prednisone 10-20 mg BID^h
- Focus on patient goals and preferences
- Provide family with alternate ways of caring for the patient
- Provide emotional support
- Treat for depression, if appropriate (mirtazapine 7.5-30 mg hs)
- Provide education and support to patient and family regarding emotional aspects of withdrawal of nutritional support.
- Inform patient and family of natural history of disease, including the following points:
 - ▶ Absence of hunger and thirst is normal in the dying patient
 - ▶ Nutritional support may not be metabolized in patients with advanced cancer
 - ▶ There are risks associated with artificial nutrition and hydration, including fluid overload, infection, and hastened death
 - ▶ Symptoms like dry mouth should be treated with local measures (eg, mouth care, small amounts of liquids)
 - ▶ Withholding or withdrawal of enteral or parenteral nutrition is ethically permissible in this setting. It will not cause exacerbation of symptoms and may improve some symptoms.

REASSESSMENT

Acceptable:

- Adequate anorexia/cachexia symptom control
- Reduction of patient/family distress
- Acceptable sense of control
- Relief of caregiver burden
- Strengthened relationships
- Optimized quality of life
- Personal growth and enhanced meaning

Unacceptable

Continue to treat and monitor symptoms and quality of life to determine whether status warrants change in strategies

- Intensify palliative care interventions
- Consult or refer to specialized palliative care services or hospice

Ongoing reassessment

Months to weeks
Weeks to days (Dying patient) →

^hDy S, Lorenz K, et al. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. 2008 J Clin Oncol 26:3886-3895.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NAUSEA AND VOMITING

ESTIMATED
LIFE
EXPECTANCY

INTERVENTIONS^{k,l}

Years

Year
to
months

Months
to
weeks^j

Weeks
to
days
(Dying
patient)^j

- Chemotherapy/radiation therapy-induced ([See NCCN Guidelines for Antiemesis](#))
- Severe constipation/fecal impaction ([See PAL-17](#))
- Gastroparesis (metoclopramide, 5-20 mg PO QID 30 min before meals and at bedtime)
- Bowel obstruction ([See PAL-18](#))
- Central nervous system (CNS) involvement (eg, brain, meninges)
 - ▶ Corticosteroids (dexamethasone, 4-8 mg BID-TID)
 - ▶ Palliative radiation therapy
- Gastric outlet obstruction from intra-abdominal tumor or liver metastasis
 - ▶ If not contraindicated by comorbid conditions, treat with corticosteroids, a proton pump inhibitor, and metoclopramide
 - ▶ Endoscopic stenting
 - ▶ Decompressing G-Tube
- Treat metabolic abnormalities
 - ▶ Hypercalcemia
 - ▶ Uremia
 - ▶ Dehydration
- Gastritis/GERD
 - ▶ Proton pump inhibitor
 - ▶ H2-blocker

- Medication-induced
 - ▶ Discontinue any unnecessary medications
 - ▶ Check available blood levels of necessary medications (eg, digoxin, phenytoin, carbamazepine, tricyclic antidepressants)
 - ▶ Treat medication-induced gastropathy (eg, proton pump inhibitor, metoclopramide)
 - ▶ If due to opioids, initiate opioid rotation and/or consider reducing opioid requirement with non-nauseating coanalgesics or procedural interventions
- Psychogenic
 - ▶ Consider psychiatric consultation if patient has an eating disorder, somatization, phobia, or panic disorder causing NV. [See NCCN Guidelines for Distress Management](#)
- Non-specific NV
 - ▶ Initiate pharmacologic management with dopamine receptor antagonists (eg, haloperidol, metoclopramide, prochlorperazine)
 - ▶ If anxiety contributes to NV, consider adding lorazepam, 0.5-1 mg q 4 hr prn
 - ▶ If oral route is not feasible, consider sublingual, rectal, subcutaneous, or intravenous administration of anti-nausea therapy
 - ▶ Consider non-pharmacologic therapies, such as acupuncture, hypnosis, and cognitive behavioral therapy

If NV stops:
[See Reassessment \(PAL-16\)](#)

If NV persists:
[See Interventions \(PAL-16\)](#)

^jIn patients with advanced cancer, NV may be secondary to the cachexia syndrome (chronic nausea, anorexia, asthenia, changing body image, and autonomic failure).

^kAn around-the-clock dosing schedule would likely provide the greatest benefit to the patient.

^lContinuous intravenous or subcutaneous infusions of different antiemetics may be necessary for the management of intractable NV.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PERSISTENT NAUSEA AND VOMITING

INTERVENTIONS

Titrate dopamine receptor antagonist (eg, prochlorperazine, haloperidol, metoclopramide, olanzapine) to maximum benefit and tolerance.

If NV persists:

Add a 5-HT₃ antagonist (eg, ondansetron) ± anticholinergic agent (eg, scopolamine) ± antihistamine (eg, meclizine) ± cannabinoid.
If NV persists:

Add a corticosteroid (eg, dexamethasone) ± olanzapine, if not already tried.
If NV persists:

Consider using a continuous IV/SC infusion of antiemetics; consider an opioid rotation if patient is on opioids.

REASSESSMENT

Acceptable:

- Adequate NV symptom control
- Reduction of patient/family distress
- Acceptable sense of control
- Relief of caregiver burden
- Strengthened relationships
- Optimized quality of life

Continue to treat and monitor symptoms and quality of life to determine whether status warrants change in strategies


Unacceptable

- Intensify palliative care interventions
- Consult or refer to specialized palliative care services or hospice
- Consider palliative sedation ([See PAL-31](#))

[Ongoing reassessment \(See Interventions, PAL-15\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



MALIGNANT BOWEL OBSTRUCTION^m

**ESTIMATED
LIFE
EXPECTANCY**

ASSESSMENT

Years

Year to
months

Months
to weeks

- Screen for and treat underlying reversible causes
 - Adhesions
 - Radiation-induced strictures
 - Internal hernias
- Assess for malignant causes
 - Tumor mass
 - Carcinomatosis
- Assess the goals of treatment for the patient, which can help guide the interventionⁿ (eg, decrease NV, allow patient to eat, decrease pain, allow patient to go home/to hospice)

[See
Interventions
\(PAL-19\)](#)

Weeks to
days
(Dying
patient)ⁿ

- Consider medical management rather than surgical management
- Assess the goals of treatment for the patient, which can help guide the interventionⁿ (eg, decrease NV, allow patient to eat, decrease pain, allow patient to go home/to hospice)
- Provide education and support to patient and family

- Pharmacologic management
- Intravenous or subcutaneous fluids
- Enteral tube drainage
 - Consider only if other measures fail to reduce vomiting
- Endoscopic management

[See
Reassessment
\(PAL-19\)](#)

^mPlain film radiography may be helpful in confirming the clinical diagnosis of bowel obstruction. Consider a computed tomography scan if surgical intervention is contemplated, as it is more sensitive and may help identify the cause of obstruction.

ⁿMost malignant bowel obstructions are partial, allowing time to discuss appropriate intervention with the patient and family.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

MALIGNANT BOWEL OBSTRUCTION

INTERVENTIONS

- **Operative management^o**
 - Risks must be discussed with the patient/family (eg, mortality, morbidity, re-obstruction)
 - Improved quality of life should be the primary goal of surgical treatment
- **Endoscopic management**
 - Percutaneous endoscopic gastrostomy tube for drainage
 - Endoscopic stent placement
- **Interventional radiology management**
 - Ultrasound-guided gastrostomy tube for drainage
- **Pharmacologic management when the goal is maintaining gut function:**
 - Use rectal, transdermal, subcutaneous, or intravenous routes of administration
 - Administer opioids: Transdermal, subcutaneous, intravenous
 - Administer antiemetics: Do not use antiemetics that increase gastrointestinal motility such as metoclopramide; however, these may be beneficial in incomplete bowel obstruction
 - Administer corticosteroids: Dexamethasone 4 mg IV TID-QID, discontinue if no improvement is noted in 3-5 days
- **Pharmacologic management when gut function cannot be maintained:**
 - Administer anticholinergics (eg, scopolamine, hyoscyamine, glycopyrrolate)
 - Administer octreotide: (100-300 mcg SC BID-TID or 10-40 mcg/hr continuous SC/IV infusion)
- **Intravenous or subcutaneous fluids**
 - Consider if there is evidence of dehydration
- **Enteral tube drainage**
 - Usually uncomfortable
 - Increased risk of aspiration
 - Consider on a limited trial basis only if other measures fail to reduce vomiting
- **Total parenteral nutrition (TPN)**
 - Consider only if there is expected improvement of quality of life with life expectancy of many months to years

REASSESSMENT



^oRisk factors for poor surgical outcome include: ascites, carcinomatosis, palpable intraabdominal masses, multiple bowel obstructions, previous abdominal radiation, very advanced disease, and poor overall clinical status.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

SLEEP/WAKE DISTURBANCES INCLUDING INSOMNIA AND SEDATION

**ESTIMATED
LIFE
EXPECTANCY**

INTERVENTIONS

- Explore fears and anxiety regarding death/disease
- Provide sleep-hygiene education
- Provide cognitive-behavioral treatment
 - ▶ Includes stimulus control, progressive muscle relaxation
- Evaluate type/severity of sleep-wake disturbance, including daytime impairments (eg, Epworth Sleepiness Scale)
- Consider polysomnography if history is suggestive of sleep-disordered breathing
- Treat contributing factors:
 - ▶ Pain, depression, anxiety, delirium, and nausea
 - ▶ Medication side effects or withdrawal syndromes (eg, corticosteroids, opioids, anticonvulsants, caffeine, hormones, herbals, barbiturates, benzodiazepines, alcohol, tricyclic antidepressants)
 - ▶ Primary sleep disorders such as obstructive sleep apnea and periodic limb movement disorder
 - ◊ CPAP/BiPAP
 - ▶ For restless leg syndrome consider trial of the following:
 - ◊ Ropinirole
 - ◊ Pramipexole
 - ◊ Carbidopa-levodopa
- Provide pharmacologic therapies for refractory sleep/wake disturbance
 - ▶ Insomnia:
 - ◊ Lorazepam, 0.5-1 mg PO at bedtime
 - ◊ Trazodone, 25-100 mg PO at bedtime
 - ◊ Zolpidem, 5 mg PO at bedtime
 - ◊ Mirtazapine^P, 7.5-30 mg PO at bedtime
 - ◊ Olanzapine, 2.5-5 mg PO at bedtime
 - ▶ Daytime sedation:
 - ◊ Caffeine 100-200 mg PO q 6 hrs, last dose 4 PM
 - ◊ Methylphenidate, start with 2.5-20 mg PO BID, second dose no later than 6 hours before bedtime
 - ◊ Dextroamphetamine, 2.5-10 mg PO BID, second dose no later than 12 hours before bedtime
 - ◊ Modafinil, 100-400 mg PO each morning

REASSESSMENT

- Acceptable:**
- Adequate control of symptoms
 - Reduction of patient/family distress
 - Acceptable sense of control
 - Relief of caregiver burden
 - Strengthened relationships
 - Optimized quality of life
 - Personal growth and enhanced meaning

Continue to treat and monitor symptoms and quality of life to determine whether status warrants change in strategies

Unacceptable

- Re-evaluate contributing etiologies
- Change insomnia or antisedation therapy
- Intensify palliative care interventions
- Consult or refer to specialized palliative care services or hospice
- Consider referral for polysomnography

Ongoing reassessment

Years

Year to months

Months to weeks

Weeks to days (Dying patient)

- Assess patient's desire to have insomnia and sedation treated
- Adjust doses of pharmacologic therapies
 - ◊ Consider chlorpromazine, 25-100 mg PO/PR at bedtime
 - ◊ Consider quetiapine 25-50 mg PO at bedtime


^PKim SW, Shin IS, Kim JM, Kim YC, Kim KS, Kim KM, Yang SJ, Yoon JS. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. *Psychiatry Clin Neurosci* 2008;62:75-83.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

DELIRIUM

**ESTIMATED
LIFE
EXPECTANCY**



Severe delirium (agitation)

Mild/moderate delirium

INTERVENTIONS

- Reduce or eliminate delirium-inducing medications as possible (eg, steroids, anticholinergics, benzodiazepines)
 - Administer haloperidol 0.5-10 mg IV q 1-4 h prn
 - Administer alternative agents: olanzapine, 2.5-7.5 mg/d PO/SL q 2-4 h prn (maximum = 30 mg/d); chlorpromazine, 25-100 mg PO/PR/IV q 4 h prn for bed-bound patients
 - If agitation is refractory to high doses of neuroleptics, consider adding lorazepam, 0.5-2 mg SQ/IV q 4 h
 - Titrate starting dose to optimal effect
 - Consider opioid dose reduction or rotation
 - Support caregivers
-
- Administer haloperidol 0.5-2 mg PO BID/TID
 - Administer alternative agents: risperidone, 0.5-1 mg PO BID; olanzapine, 5-20 mg PO daily; or quetiapine fumarate, 25-200 mg PO/SL BID
 - Titrate starting dose to optimal effect
 - Orient patient with family presence

REASSESSMENT


- Acceptable:
- Adequate delirium symptom control
 - Reduction of patient/family distress
 - Acceptable sense of control
 - Relief of caregiver burden
 - Strengthened relationships
 - Optimized quality of life
 - Personal growth and enhanced meaning

Unacceptable

- Continue to treat and monitor symptoms and quality of life to determine whether status warrants change in strategies, including tapering of doses
-
- Intensify palliative care interventions
 - Consider consultation with a palliative care specialist or psychiatrist

Ongoing reassessment

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




SOCIAL SUPPORT/RESOURCE MANAGEMENT


ESTIMATED
LIFE
EXPECTANCY

INTERVENTIONS

REASSESSMENT




Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

GOALS AND EXPECTATIONS, EDUCATIONAL AND INFORMATIONAL NEEDS, AND CULTURAL FACTORS AFFECTING CARE FOR THE PATIENT AND FAMILY




Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[See Advance Care Planning \(PAL-27\)](#)



GOALS AND EXPECTATIONS, EDUCATIONAL AND INFORMATIONAL NEEDS, AND CULTURAL FACTORS AFFECTING CARE FOR THE PATIENT AND FAMILY



Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ADVANCE CARE PLANNING

ESTIMATED LIFE EXPECTANCY

INTERVENTIONS

- Ask patient if he/she has a living will, medical power of attorney, health care proxy, or patient surrogate for health care
 - ▶ If not, encourage patient to prepare one
- Explore fears about dying and address anxiety
- Assess decision-making capacity and need for surrogate decision-maker
- Initiate discussion of personal values and preferences for end-of-life care
- If patient values and goals lead to a clear recommendation regarding future treatment in light of disease status, physician should make a recommendation about future care
- Document patient values and preferences and any decisions in accessible site in medical record (including MOLST/POLST if completed)
- Encourage the patients to discuss wishes with family/proxy
- Initiate discussion of palliative care options, including hospice if appropriate
- Introduce palliative care team if appropriate
- Refer to state and institutional guidelines for additional guidance

REASSESSMENT

- Acceptable:**
- Adequate advance care planning
 - Reduction of patient/family distress
 - Acceptable sense of control
 - Relief of caregiver burden
 - Strengthened relationships
 - Optimized quality of life
 - Personal growth and enhanced meaning

Ongoing re-evaluation and communication between the patient and health care team

Unacceptable

- Explore patient reluctance to engage in advance care planning
- Explore fears and worries about illness
- Refer to palliative care if the patient is having difficulty engaging in discussion of advance care planning
- Consider referral to a mental health clinician to evaluate mental health issues
- [See NCCN Guidelines for Distress Management](#)

Ongoing reassessment

Years


Year to months

Months to weeks

Weeks to days (Dying patient)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



RESPONSE TO REQUESTS FOR HASTENED DEATH (PHYSICIAN AID-IN-DYING, PHYSICIAN-ASSISTED SUICIDE, EUTHANASIA)

- **The NCCN Palliative Care Panel believes that the most appropriate response to a request for assistance in suicide is to intensify palliative care. All such patients should be referred to a palliative care specialist. However, evaluating a patient's request for physician-assisted suicide is an important skill, even for clinicians who feel this practice is never morally acceptable. A request for hastened death often has important meanings that require exploration. Clarifying these meanings can sometimes enlarge the range of useful therapeutic options instead of providing a lethal prescription.**
- **Address the request explicitly. If a patient uses a euphemism for death or refers to it indirectly, ask for clarification. Do not assume that a wish for death to come soon is a wish for a lethal prescription.**
- **Distinguish wishing not to live in the patient's current state from wishing for a hastened death including euthanasia and physician-assisted suicide.**
- **Explore the reasons for the request for a hastened death, and find out "why now?"**
 - **Reassess symptom control.**
 - **Reassess psychological/psychiatric issues, especially depression, anxiety, grief, psychosis, and delirium.**
 - **Ask about the patient's relationship to family or other important people.**
 - **Ask about individual values and personal views of spiritual/existential suffering.**
 - **Assess for fears of caregiver burden and abandonment and re-emphasize physician commitment to the patient.**
- **Offer information about the natural history of the disease and explain the process of dying.**
- **Address the role of medical caregivers, including hospice if appropriate.**
- **Discuss alternatives to physician-assisted suicide such as withdrawal of life-sustaining treatment, voluntary cessation of eating or drinking, and/or sedation for refractory symptoms.**
- **Request a consult with a mental health professional to diagnose and treat reversible causes of psychological suffering.**
- **Know the local legal status of hastened death. Some patients may be confused about legal/ethical distinctions; treatment withdrawal and aggressive treatments for symptoms, such as pain, are not physician-assisted suicide. Physician-assisted suicide is legal only in Oregon, Montana, Vermont, and Washington and has specific guidelines. Euthanasia is not legal in any state in the United States.**
- **Examine your own response as a clinician to a particular patient's request. Requests for hastened death can force clinicians to confront their own personal, professional, moral, and legal responsibilities. Dealing with an individual patient can be quite different from thinking about the issue in abstract circumstances. Consider a consultation with an ethics committee, palliative care service, or experienced colleague. These cases are usually complex and often benefit from consideration of multiple perspectives.**
- **Clarify the care plan. Requests for hastened death should prompt ongoing discussion and active attempts to ameliorate physical, psychological, and spiritual distress. Re-emphasize your own commitment to providing continuing care for the patient. Maintain medications for symptom control.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**CARE OF THE IMMINENTLY DYING PATIENT**

For an imminently dying patient, consider using an end-of-life care order set, which may contain physical, psychosocial, and practical interventions, including the following:

• Physical

- ▶ **Intensify comfort measures:**
 - ◊ Implement skin safety protocol according to risk assessment, including using a pressure-relieving mattress and regularly repositioning the patient for comfort as indicated; keep skin moist; reassess wound care for comfort; and premedicate for wound care as needed
 - ◊ Provide mouth care to keep mouth/lips moist
 - ◊ Treat for urinary retention and fecal impaction
- ▶ Ensure deactivation of implanted defibrillator and consider deactivation of implanted pacemaker
- ▶ Discontinue unnecessary diagnostic tests and interventions such as transfusions, needle sticks, blood glucose monitoring, oxygen saturation monitoring, and suctioning
- ▶ Replace check of vital signs with regular (eg, every 4 h) symptom control assessments
- ▶ Switch routes of medication administration when the oral route is no longer feasible
- ▶ Adjust doses of medications to optimal comfort
- ▶ Treat unclearable terminal secretions (death rattle) by changing the patient's positioning and reducing parenteral and enteral fluids.
 - ◊ For refractory secretions ([See PAL-12](#))
- ▶ Treat dyspnea by adjusting the dose of medication ([See PAL-11](#))
- ▶ Treat refractory restlessness and agitation with palliative sedation ([See PAL-31](#))
- ▶ Prepare to meet a request for organ donation and autopsy

• Psychosocial

- ▶ Help support the patient and family to accept discontinuation of TPN and transfusions, dialysis, IV hydration, and medications that will not add to the patient's comfort
- ▶ Consider social work and chaplain consults
- ▶ Allow the patient and family to have uninterrupted time together
- ▶ Ensure that the patient and family understand the signs and symptoms of imminent death and that they are supported throughout the dying process
- ▶ Offer anticipatory bereavement support
- ▶ Provide support to children and grandchildren
- ▶ Encourage visits by children if consistent with family values
- ▶ Support culturally meaningful rituals
- ▶ Ensure that caregivers understand and will honor advance directives
- ▶ Facilitate closure

• Practical

- ▶ Mobilize in-hospital end-of-life care policies and procedures
- ▶ Ensure that the patient's advance directives are documented and implemented
- ▶ Recommend that the patient's wishes for resuscitation and/or do-not-attempt-resuscitation (DNAR) are documented and followed
 - ◊ If the patient/family have not documented a DNAR order, intensify patient/family education, counsel the family on the importance of a DNAR, or allow natural death (AND)
- ▶ Ensure privacy for the patient and family; if not at home, arrange for a private room if possible
- ▶ Facilitate around-the-clock family presence
- ▶ Provide the patient and family with respectful space and uninterrupted time together
- ▶ Facilitate funeral planning

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[See After-Death Interventions \(PAL-32\)](#)



PALLIATIVE SEDATION

- **Confirm that the patient has refractory symptoms and is imminently dying.**
 - ▶ **Refractory symptoms are symptoms that cannot be adequately controlled despite aggressive, skilled palliative care that does not compromise consciousness.**
 - ▶ **Imminently dying is a prognosis of hours to days confirmed by two physicians.**

- **Obtain informed consent for sedation from the patient and/or surrogate/family.**
 - ▶ **Discuss the patient's disease status, treatment goals, prognosis, and expected outcomes with the patient and/or surrogate.**
 - ▶ **Clarify that sedation will consist of the continuous administration of medications that will render the patient unconscious.**
 - ▶ **Review the ethical justification of the use of sedation with the patient/surrogate/family and members of the health care team.**
 - ◊ **An ethics consult may be considered in accordance with institutional guidelines and state regulations.**
 - ▶ **Explain that consent for sedation must be accompanied by consent for:**
 - ◊ **Discontinuation of life-prolonging therapies**
 - ◊ **Withholding of cardiopulmonary resuscitation**

- **Permit reassignment of health care professionals who cannot provide sedation due to personal or professional values and beliefs as long as patient care can be safely transferred to the care of another health care professional.**

- **Select an appropriate sedative treatment plan based upon the patient's response to recent and current medications.**

Typical sedatives used for palliative sedation parenteral infusions include:

 - ▶ **Thiopental: Initial infusion rate 20-80 mg/h; range 160-440 mg/h**
 - ▶ **Pentobarbital: Initial infusion 2-3 mg per kg load then 1-2 mg per kg/h**
 - ▶ **Midazolam: Initial infusion rate 0.4-0.8 mg/h; range 20-102 mg/h**

- **Continue current pain and symptom management control interventions.**

- **Monitor patient symptoms regularly and titrate sedatives and other medications based on response and drug/drug interactions to establish and maintain a level of sedation that relieves the patient's refractory symptoms.**

- **Provide ongoing psychosocial and spiritual support for the patient's surrogate, family, and health care professionals.**

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



DEATH

ASSESSMENT

AFTER-DEATH INTERVENTIONS



Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview.....	MS-2
Palliative Care in Oncology.....	MS-2
The Definition of Palliative Care	MS-2
Impact of Palliative Care	MS-3
Provision of Palliative Care.....	MS-4
Hospice Care	MS-4
Palliative Care Standards	MS-5
Barriers to Timely Provision of Palliative Care	MS-6
Training in Palliative Care	MS-7
Communication Skills Training.....	MS-7
NCCN Guidelines for Palliative Care.....	MS-8
Palliative Care Screening	MS-8
Palliative Care Assessment.....	MS-9
Assessment for Benefits and Risks of Anticancer Therapy	MS-9
Assessment of Personal Goals and Expectations	MS-9
Assessment of Physical Symptoms	MS-9

Assessment of Psychosocial Distress.....	MS-9
Assessment of Educational and Informational Needs and Cultural Factors Affecting Care	MS-9
Criteria for Consultation with Palliative Care	MS-9
Palliative Care Interventions	MS-10
Anticancer Therapy	MS-11
Symptom Management	MS-12
Pain	MS-12
Dyspnea	MS-13
Anorexia/Cachexia.....	MS-14
Nausea and Vomiting.....	MS-15
Constipation.....	MS-16
Malignant Bowel Obstruction	MS-16
Fatigue/Weakness/Asthenia	MS-17
Sleep/Wake Disturbances.....	MS-17
Delirium	MS-18
Psychosocial Distress – Social Support/Resource Management	MS-19
Advance Care Planning	MS-20
Palliative Care Reassessment	MS-21
Special Palliative Care Interventions.....	MS-21
Requests for Hastened Death	MS-21
Palliative Sedation.....	MS-22
Care of the Imminently Dying Patient	MS-22
A Peaceful Death	MS-23
After-Death Care Interventions	MS-23
Palliative Care Research	MS-24
Putting Palliative Care Guidelines into Practice	MS-24
Psychosocial Support for Palliative Care Providers	MS-26
Hope.....	MS-26
Table 1: Palliative Care Internet Resources for Clinicians ^a	MS-28
References	MS-29



Overview

The aim of the NCCN Guidelines for Palliative Care is to help assure that each patient with cancer experiences the best quality of life possible throughout the illness trajectory by providing guidance for the primary oncology team. The NCCN Palliative Care Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical oncologists, hematologists and hematologic oncologists, pediatric oncologists, neurologists and neuro-oncologists, anesthesiologists, psychiatrists and psychologists, internists, palliative care and pain management specialists, and geriatric medicine specialists. These guidelines were developed and are updated annually by the collaborative efforts of these experts based on their clinical experience and available scientific evidence.

Palliative Care in Oncology

More than 1.65 million people are expected to be diagnosed with cancer in the United States in 2014, and almost 0.6 million people are expected to die of the disease.¹ Global cancer rates are increasing, with an associated rise in the number of cancer survivors living with symptoms and disabilities as a result of their disease and/or its treatment (see the [NCCN Guidelines for Survivorship](#)).²⁻⁴ The need for comprehensive care for patients with cancer and their families is great. Approximately 16% of patients with cancer being discharged from a single hospital in Germany were assessed as having palliative care needs, with the greatest needs in patients with head and neck cancer, melanoma, and brain tumors.⁵ More than one-third of patients with cancer in a large observational cohort study reported moderate to severe symptoms in the majority of categories (pain, nausea, anxiety, depression, shortness of breath, drowsiness, well-being, loss of appetite, and tiredness) in the last weeks of life.⁶ Thus, the need for palliative oncologic care is great.

Palliative care in oncology mainly began as hospice and end-of-life care. During the past 20 years, increasing attention has been paid to quality-of-life issues in oncology throughout the disease trajectory.^{3,7-11} As the hospice movement has grown in this country, palliative care has developed into an integral part of comprehensive cancer care.^{3,12-16}

The Definition of Palliative Care

These guidelines define palliative care as a special kind of patient- and family-centered health care that focuses on effective management of pain and other distressing symptoms, while incorporating psychosocial and spiritual care according to patient/family needs, values, beliefs, and culture(s). The goals of palliative care are to anticipate, prevent, and reduce suffering and to support the best possible quality of life for patients and their families, regardless of the stage of the disease or the need for other therapies. Palliative care begins at diagnosis and should be delivered concurrently with disease-directed, life-prolonging therapies and should facilitate patient autonomy, access to information, and choice. Palliative care becomes the main focus of care when disease-directed, life-prolonging therapies are no longer effective, appropriate, or desired. Palliative care should be initiated by the primary oncology team and then augmented by collaboration with an interdisciplinary team of palliative care experts.

Building on the WHO's recommended model of resource allocation in cancer care,¹² a 1999 NCCN Task Force recommended that palliative, symptom-modifying therapy should be provided simultaneously with disease-modifying therapy from diagnosis.¹⁷ While palliative care previously focused on end-of-life care, the idea that palliative care needs to be integrated earlier into the continuum of cancer care is increasingly understood.¹⁸⁻²² Palliative care needs to exist right from the time of diagnosis through survivorship and/or end-of-life care. Palliative



care should begin with the presentation of symptoms, even before the source of those symptoms has been fully determined. As the cancer progresses and anticancer therapy becomes less effective, appropriate and desired palliative care becomes the major focus of the continuing care of the patient and family.²³ Patients with increased risk for cancer should also be provided with supportive care along with risk-reduction therapies. Palliative care should continue even after the patient's death in the form of bereavement support for the patient's survivors.

Impact of Palliative Care

A remarkable study showed that early introduction of palliative care can not only improve quality of life for patients with advanced cancer but can also improve survival.²⁴ A secondary analysis of this study further showed that patients receiving early palliative care were less likely to receive chemotherapy in the last 60 days of life (odds ratio, 0.47; 95% CI, 0.23 to 0.99; $P = .05$),²⁵ likely because these patients had a more accurate understanding of their prognosis, which impacted decisions about their care.²⁶

Palliative care consultations in patients with advanced cancers have also been shown to reduce the quantity and intensity of life-prolonging care received towards the end of life. In one study, early referral to community-based palliative care services reduced the number of emergency department visits in the last 90 days of life in patients with cancer.²⁷ Likewise, in another study, the lack of palliative care team consultation was shown to be a predisposing factor for futile life-sustaining treatments at the end of life.²⁸ Moreover, in a cohort of 6076 patients with advanced pancreatic cancer, patients who had received at least one palliative care consultation had lower odds of intensive care unit (ICU) admission, multiple emergency department visits, and multiple hospitalizations near death.²⁹

Palliative care has been shown to reduce symptom burden, improve quality of life, and increase the odds of dying at home. In a recent study comparing standard care with ongoing palliative care in patients with advanced cancer who had a prognosis of 6 to 24 months to live, palliative care resulted in improved patient quality of life, satisfaction with care, and decreased symptom severity.³⁰ Furthermore, a recent Cochrane Database systematic review analyzing home palliative care in patients with advanced illness demonstrated reliable reduction of symptom burden and increased likelihood of dying at home without a negative impact on caregiver grief.³¹ Finally, a study by Kamal and colleagues showed that provider conformance with supportive care quality measures significantly improved quality of life for patients with cancer who were receiving palliative care.³²

Provider education and training in palliative care can also positively impact providers and patients. The OPTIM (Outreach Palliative Care trial of Integrated Regional Model) study is a multiregional, mixed-methods study that examined the effects of a palliative care intervention implemented across 4 regions of Japan.³³ The intervention consisted of provider education and training; education and awareness initiatives for the general public/patients; establishment of community-based palliative care teams to instruct community health care institutions; and establishment of regional palliative care centers to coordinate multidisciplinary community resources. Surveys were provided to patients, bereaved family members, physicians, and nurses both before and after the intervention; the results indicated an increased percentage of patients receiving palliative care and dying at home, increased patient- and family-reported quality of care, and decreased physician- and nurse-reported difficulties in providing palliative care.

Overall, research suggests that successful integration of palliative care early in the continuum of care reduces morbidity for patients with cancer



and enhances patient and family/caregiver satisfaction (reviewed by Rocque and Cleary³⁴ and Khan, et al.³⁵).

In February 2012, ASCO published a provisional clinical opinion, based on 7 randomized controlled trials and expert consensus.³⁶ The ASCO panel stated that there is substantial evidence to show that “palliative care—when combined with standard cancer care or as the main focus of care—leads to better patient and caregiver outcomes.” The ASCO panel concluded that strong consideration should be given to the integration of palliative care with standard oncology care early in the course of illness for patients with metastatic cancer and/or high symptom burden.

Provision of Palliative Care

Initially, the primary oncology team (interdisciplinary team of physicians, nurses, social workers, other mental health professionals, chaplains, physician assistants, pharmacists, and dietitians) can provide most of the palliative care needed by the patient and family. Intractable symptoms or complex psychosocial problems can benefit from the inclusion of palliative care experts.

Palliative care should be integrated into patient care through collaboration between the primary oncology team and palliative care specialists as needed over the course of disease.³⁷ Additionally, palliative care efforts should reach beyond the patient, to family and caregivers.

When further anti-cancer therapy is likely to do more harm than good, palliative care becomes the predominant care offered to patients with advanced cancer. When possible, inpatient palliative care can facilitate transfer to home hospice or inpatient hospice care. For patients too unstable for transfer out of the inpatient setting, palliative care provides

end-of-life care for patients who die in the hospital. Several groups have described their ideas and approaches for, experience and outcomes with, and barriers to developing successful programs that integrate palliative care into routine oncologic care.^{21,22,37-47}

Hospice Care

Hospice is the most established model of palliative care for patients with a prognosis of less than 6 months and is eligible for coverage by third-party payers and Medicare. Enrollment in hospice has been shown to reduce hospitalization and receipt of high-intensity nonhospice care at the end of life. An analysis of the SEER database revealed that men with advanced prostate cancer who were enrolled in hospice were less likely to receive high-intensity care, including ICU admission and inpatient stays, at the end of life.⁴⁸ Moreover, a study of 207 deceased patients with cancer who had stopped cancer treatment showed reduced emergency department visits, hospitalizations, and other noncancer clinic visits among patients enrolled in hospice.⁴⁹ Additionally, analyses of data from 3069 deceased patients over 50 years of age (extracted from the Health and Retirement Study) revealed that hospice enrollment significantly decreased hospitalization, non-hospice health care utilization, and cost of care.⁵⁰

According to the National Home and Hospice Care Survey, the number of adult patients with cancer using hospice care tripled during 1991 through 1992 to 1999 through 2000.⁵¹ The 2013 edition of *NHCPO Facts and Figures: Hospice Care in America* states that 43.3% of Medicare decedents with a cancer diagnosis accessed ≥ 3 days of hospice in 2007, increasing from 36.6% in 2001.⁵² However, the median length of hospice service was just under 19 days in 2012.⁵² Most patients who receive hospice care in this country are referred too late for hospice care to exert its full benefit, and many patients are never



referred at all.^{48,53} A recent study of Medicare patients with advanced lung cancer in New York and California suggested that hospice was underutilized, with a significant proportion of patient deaths occurring without enrollment in hospice.⁵⁴

End-of-life care can often be more aggressive than what is supported by current evidence. Generally, Medicare patients with poor-prognosis cancer received highly intensive end-of life-care.⁵⁵ Furthermore, administration of chemotherapy late in the course of cancer care, including in the last days of life, is growing more common,^{56,57} and oncologists have reported that they have found hospice regulations and reimbursement limitations too restrictive.⁵⁸ Overall, provision of end-of-life care was inconsistent and varied widely across regions, even among comprehensive cancer centers.^{55,59}

Palliative Care Standards

Assessing outcomes and evaluating palliative cancer care is essential to ensure high-quality, evidence-based care. Lorenz et al performed a systematic review of end-of-life care and outcomes and found that many aspects of palliative care lack high-quality evidence.⁶⁰ The third edition of the Clinical Practice Guidelines for Quality Palliative Care by the National Consensus Project was published in 2013,⁶¹ and the National Quality Forum has developed a national quality framework for evaluating palliative care programs, extending beyond terminally ill patients with cancer to include a broad spectrum of patients with multiple illnesses.⁶² These guidelines provide an in-depth assessment of many issues surrounding palliative care (eg, cultural, ethical, legal, physical, psychological, social, spiritual, and existential aspects of care). In addition, the American College of Physicians has developed evidence-based guidelines to improve palliative care of pain, dyspnea, and depression experienced at the end of life.⁶³

In the United Kingdom in 2004, the National Consensus Project and the National Institute for Health and Clinical Excellence (NICE) issued guidance on how supportive and palliative care services should be provided for adults with cancer (www.nice.org.uk/page.aspx?o=csgsp).

Some of the key recommendations are listed below:

1. Patients and their caregivers should have access to a range of specialist services that help them cope with cancer and its treatment.
2. Whenever possible, significant information should be given to patients by a senior health professional who has received advanced-level training and is assessed as being an effective communicator.
3. Good-quality information should be available free of charge to help people affected by cancer make decisions about their care.

ASCO recently published a statement on individualized care for patients with advanced cancer.¹⁰ While significant improvements over the past decade were noted (eg, improvements in palliative care education and training for oncologists; an increase in hospital-based palliative care programs and community-based hospice organizations), the statement points out that conversations with patients about their palliative needs are still happening too late in the progression of their disease. Some of the key elements of individualized care listed in the report state that patients should be given:

- enough information to enable them to make informed choices regarding their treatment;
- encouragement to focus on symptom-directed palliative care when disease-directed therapies fail;
- the opportunity to participate in clinical trials that may improve their outcome or that of future patients; and
- the opportunity to die with dignity and peace of mind.

In August 2011, the Commission on Cancer (CoC) of the American College of Surgeons (ACS) released new accreditation standards for hospital cancer programs (<http://www.facs.org/news/2011/coc-standards0811.html>).⁶⁴ Their patient-centered focus requires that patients have access to palliative and hospice care, psychosocial support, and pain management—either on-site or by referral. The standards also state that palliative care should be provided by an interdisciplinary team of medical and mental health professionals, social workers, and spiritual counselors and should be available beginning at the time of diagnosis and continuously throughout treatment, surveillance, and bereavement.

Barriers to Timely Provision of Palliative Care

The major reason for delayed referral to Palliative Care is professional and public confusion about the definition of Palliative Care. WHO first defined palliative care as care aimed at improving quality of life.¹² WHO expanded its earlier definition of palliative care as an approach that improves the quality of life of patients and their families facing life-threatening illness through the prevention, assessment, and treatment of pain and other physical, psychosocial, and spiritual problems.⁶⁵ The definition of palliative care in this Guideline (PAL-1) is adapted from the National Consensus on Palliative Care and the National Quality Forum Framework for Palliative Care.^{61,62} Hospice is the oldest and most widely utilized model of palliative care in the United States. Its primary focus is on patients with a prognosis of 6 months or less, for whom no further life-prolonging therapy is appropriate or desired, and who have the desire and capacity to spend most of their final months at home. Patients with cancer accounted for the largest percentage of hospice patients in the late 1970s but now account for only 37% of patients receiving hospice care in this country.⁵² Despite the 6-month prognosis

eligibility, the median length of service for hospice patients in 2012 was 18.7 days with an average stay of 71.8 days. Approximately 36% of hospice patients died or were discharged within 7 days of admission to hospice care.⁵²

Despite the growth of clinical and academic palliative care over the past two decades and the efforts of most palliative care organizations clarifying that palliative care should be given at the time of diagnosis or when there are poorly controlled symptoms regardless of prognosis, many people think that palliative care still refers only to care given at the end of life, leading to an inappropriate association of palliative care with death.⁶⁶⁻⁶⁹ Supportive care has been suggested as an alternative name, to help break this association and facilitate earlier use of palliative care for patients in need. Supportive care in cancer initially focused on the support of patients receiving active cancer therapy with antiemetics, antibiotics, bone marrow stimulants, and transfusions.⁷⁰ However, some studies suggest that patients and providers may prefer supportive care terminology to refer to palliative care services.^{71,72} At MD Anderson Cancer Center, a switch in the service name from “Palliative Care” to “Supportive Care” was associated with increased patient referrals, referrals at an increased interval before death, and referrals earlier in the course of disease.⁷³ Regardless of the terminology, patients and families should be informed that palliative care is an integral part of their comprehensive cancer care.^{66,74,75}

A retrospective review of patients with advanced cancer seen at MD Anderson Cancer Center found that only 45% of patients had a palliative care consultation before death, and many of those occurred close to death.⁷⁶ Similarly, a retrospective study of 6076 patients with advanced pancreatic cancer revealed that only 52% of patients received a palliative care consultation.²⁹ Interestingly, in a recent survey only 37% of physicians reported that they had access to a specialized

palliative care service that accepted patients on chemotherapy.⁷⁷ Thus, barriers to early referrals still exist (reviewed by Davis et al.²²). The American Academy of Hospice and Palliative Medicine (www.aahpm.org), founded in 1988, and the Center to Advance Palliative Care (www.capc.org), established in 1999, are organizations dedicated to advancing the discipline of hospice and palliative medicine. These organizations seek to expand access to quality palliative care services in hospitals and other health care settings for people with advanced illness.

Training in Palliative Care

Educational programs should be provided to all health care professionals and trainees so they can develop effective palliative care knowledge, skills, and attitudes. The number of palliative care programs in the United States is rapidly increasing. The establishment of hospice and palliative medicine as a medical subspecialty in 2008 received support from at least 10 cosponsoring American Board of Medical Specialties (ABMS; www.abms.org) boards, including Anesthesiology, Family Medicine, Internal Medicine, Physical Medicine and Rehabilitation, Psychiatry and Neurology, Surgery, and Pediatrics. Support for expansion of palliative medicine education has been offered by the Liaison Committee on Medical Education (LCME; www.lcme.org), which has mandated palliative medicine education for medical schools. In addition, the Accreditation Council for Graduate Medical Education (ACGME; www.acgme.org) now requires training in palliative medicine for oncology fellows, including training in pain, psychosocial care, personal awareness, and hospice care.

Researchers at a large urban teaching hospital recently demonstrated the effectiveness of education on palliative care and referral criteria for increasing overall referrals to palliative care services and enhanced

referrals for the purpose of pain management.⁷⁸ Effective training in palliative care can also positively impact provider, patient, and caregiver quality of life. One study suggested that an online palliative care education intervention for primary care physicians led to measurable improvements in patient outcomes such as pain, symptoms, and quality of life.⁷⁹ In a survey study, oncology fellows reported that training on end-of-life issues and goal-of-care discussions mitigated burnout and distress.⁸⁰

Another recent survey of 254 hematology/oncology fellows found that palliative care education is still lacking, with only 32% of respondents reporting formal training in managing end-of-life depression and only 33% reporting explicit training in opioid rotation.⁸¹

Palliative care resources that may be useful for clinicians are listed in Table 1, below.

Communication Skills Training

Clear, consistent, and empathetic communication with the patient and family about the natural history of the cancer and its prognosis is at the core of effective palliative care.⁸²⁻⁸⁴ It is important to assess and reassess patient goals and preferences regarding communication of difficult news over the course of disease.⁸⁵ When patients understand the goals of treatment, they can make choices that are consistent with their life goals. In addition, effective patient-physician communication can decrease patient stress, increase adherence to treatment, and improve outcomes.^{86,87} Open communication with relatives or caregivers of patients with cancer is also critical, particularly when patients near the end of life. A nationwide survey of cancer-bereaved children demonstrated that this population valued communication of medical information about disease, treatment, and death; the results showed that communication of this information prior to their loss improved

children's trust in the care provided and decreased their depression rates.⁸⁸

However, doctors are often hesitant to have honest discussions with their patients, in part because these discussions can be very difficult and emotionally draining for the physicians.⁸⁹ Survey data from 620 oncologists revealed a high level of perceived burden regarding discussions about discontinuing anticancer treatments, and many indicated a desire for additional communication skills training.⁹⁰ A recent survey of 1193 patients in the Cancer Care Outcomes Research and Surveillance (CanCORS) study found that 69% of patients with advanced lung cancer and 81% of those with advanced colorectal cancer thought that their palliative chemotherapy could cure them.⁹¹ While it is unclear whether these patients were told their prognosis, if they did not understand or choose to understand the information, or if they merely answered the survey with a high degree of optimism,⁹² this result demonstrates a clear need for improvement in the area of physician-patient communication. Similar misconceptions also apply to palliative radiation therapy. In a study of 384 patients with inoperable lung cancer, 64% of patients did not understand that their radiation therapy was not curative.⁹³

Training in communication has been shown to improve clinician communication skills⁹⁴⁻⁹⁷ and to possibly decrease physician burnout and improve physician empathy and mood.⁹⁸ For example, a recent randomized controlled trial showed that an 11-hour communication skills training workshop for oncologists was effective at improving communication skills, including those specific to the transition to palliative care.⁹⁹

NCCN Guidelines for Palliative Care

The NCCN Guidelines for Palliative Care were developed to facilitate the appropriate integration of palliative care into oncology practice. The guidelines outline procedures for screening, assessment, palliative care interventions, reassessment, and after-death care. The panel initially focused on the needs of patients in their last 12 months of life. The panel chose this period to distill the content of textbooks and curricula into guidelines that could facilitate clinical decision-making in the same way that NCCN disease-oriented and symptom-oriented guidelines have. More recent versions of these guidelines have expanded the focus to all patients and family experiencing cancer throughout the disease trajectory, consistent with the Provisional Clinical Opinion from ASCO.³⁶

Palliative Care Screening

The primary oncology team should screen all patients at every visit for: 1) uncontrolled symptoms; 2) moderate to severe distress related to cancer diagnosis and therapy; 3) serious comorbid physical, psychiatric, and psychosocial conditions; 4) life expectancy of 6 months or less; and/or 5) patient or family concerns about the course of disease and decision-making. Patients who meet these screening criteria and those who make a specific request for palliative care should undergo a full palliative care assessment.

Patients who do not meet these screening criteria should be re-screened at the next visit. In addition, the oncology team should inform patients and their family members about palliative care services. Anticipation of palliative care needs and prevention of symptoms should also be discussed, and conversations regarding advance care planning should be initiated.

Palliative Care Assessment

Patients who meet screening criteria (see above) should undergo a comprehensive palliative care assessment by their primary oncology team evaluating the benefits and risks of anticancer therapy; physical symptoms; psychosocial or spiritual distress; personal goals and expectations; educational and informational needs; and cultural factors affecting care.⁷⁻⁹

Assessment for Benefits and Risks of Anticancer Therapy

Many cancer symptoms can be relieved by control of the cancer with anti-cancer therapy. Assessment of the benefits and risks of anticancer therapy for each individual is based on the existing NCCN disease-specific guidelines (the most recent version of all guidelines can be found on the NCCN website at www.NCCN.org). Special attention should be given to the natural history of the specific tumor; the potential for response to further treatment; the meaning of anticancer therapy to the patient and family; the potential for treatment-related toxicities including impairment of vital organs and performance status; and serious comorbid conditions. Specific recommendations regarding anticancer therapy for patients with various life expectancies are discussed in *Palliative Care Interventions*, below.

Assessment of Personal Goals and Expectations

Patients and their families should also be asked about their personal goals and expectations. Their priorities for palliative care, including their goals and perceived meaning of anticancer therapy and the importance they place on quality of life, should be assessed. Goals and expectations that might be better met by the hospice model of palliative care should be identified. When appropriate, it is important to determine the patient's understanding of the incurability of their disease and whether patients wish to know survival statistics.

Assessment of Physical Symptoms

The most common symptoms that need to be assessed are pain, dyspnea, anorexia, cachexia, nausea, vomiting, constipation, malignant bowel obstruction, fatigue, weakness, asthenia, insomnia, daytime sedation, and delirium.¹⁰⁰ Palliative interventions for these symptoms are discussed individually below.

Assessment of Psychosocial Distress

Assessment of psychosocial distress should focus on illness-related distress and psychosocial, spiritual, or existential issues according to the [NCCN Guidelines for Distress Management](#). Special problems with social support and resources (ie, home, family, community, or financial issues) must also be assessed. Recommendations for the management of psychosocial distress can be found below and in the NCCN Guidelines for Distress Management.

Assessment of Educational and Informational Needs and Cultural Factors Affecting Care

The values and preferences of patients and families about information and communication should also be assessed. The oncology team should inquire about cultural factors affecting care and perceptions of the patient/family regarding the patient's disease status.

Criteria for Consultation with Palliative Care

Criteria for consultation with a palliative care specialist are based on patient characteristics, social circumstances, and anticipatory bereavement issues. The oncology team should consider consultation for patients with limited treatment options; non-pain symptoms that are suboptimally controlled by conventional management or a high symptom burden; history of allergies or adverse effects to multiple palliative interventions; frequent emergency department visits or hospital readmissions; complicated ICU admissions (multi-organ system



failure or prolonged mechanical ventilation); palliative stenting/gastrostomy; a high distress score (eg, ≥ 4 on the Distress Thermometer; see the [NCCN Guidelines for Distress Management](#)); cognitive impairment; severe comorbid conditions; or communication barriers. In addition, consultation with palliative care specialists should be considered for those at high risk for poor pain control: those who make a request for hastened death; and/or those who are resistant to engaging in advance care planning.

Social circumstances or anticipatory bereavement issues that indicate a need for referral for consultation with a palliative care specialist include family/caregiver limitations, inadequate social support, financial limitations, limited access to care, family discord, intensely dependent relationships, financial limitations, limited access to care, patient's concern regarding care of dependents, spiritual or existential distress, and/or unresolved or multiple prior losses.

Palliative care consultation should also be considered when staff issues, such as compassion, fatigue, or moral distress, are present. For more information regarding psychosocial issues affecting care providers, see section on *Psychosocial Support for Palliative Care Providers*.

Palliative Care Interventions

The oncology team should initiate palliative treatments following the specific recommendations described in these guidelines for common symptoms. Comorbid physical and psychosocial conditions should be treated by appropriate clinicians. Consultation or collaboration with palliative care specialists or teams is recommended for patients with more complex problems to improve their quality of life and survival.^{24,36}

Referrals should be made as needed to mental health and social services, pastoral care, health care interpreters, hospice services, or

other specialists. Finally, the oncology team can be helpful in mobilizing community support through religious organizations, schools, or community agencies.

The panel divided patients into 3 groups to address the effect of life expectancy on the delivery of palliative care interventions: 1) patients with years to months to live; 2) patients with months to weeks to live; and 3) dying patients in their final weeks to days. Patients in their final hours of life are referred to as *imminently dying* and may require special interventions. The panel recognizes the lack of precision in estimating life expectancy but believes that this delineation will be useful for the delivery of appropriate palliative care interventions. The patient and family's personal, spiritual and existential, cultural, and religious goals and expectations may change throughout these timeframes. Optimal provision of palliative care requires ongoing reassessment and modification of strategies, as well as ongoing communication between the patient, family, and health care team.

Indicators that patients are in their last 6 months of life include decreased performance status (ECOG score ≥ 3 ; KPS score ≤ 50), hypercalcemia, central nervous system metastases, delirium, superior vena cava syndrome, spinal cord compression, cachexia, malignant effusions, liver failure, kidney failure, or other serious comorbid conditions. Many patients with stage IV cancers, especially those with metastatic lung cancer, pancreatic cancer, and glioblastoma multiforme, would benefit from palliative care beginning at diagnosis, because expected survival is limited.¹⁰¹⁻¹⁰³

For patients whose life expectancy is “years to months” or “months to weeks,” it is important to determine how much information a patient wishes to know and how much of that information should be shared with the patient's family. In patients queried regarding preferences about

receiving prognostic information and detailed information on their disease, studies show that the majority express a desire to receive this information.¹⁰⁴⁻¹⁰⁷ Patients will also require answers to any questions about what to expect in the next few months and anticipatory guidance on the dying process. In addition, determining the decision-making styles of patients and their families helps facilitate congruence of a patient's goals and expectations with those of the family. Clinicians should also determine the patient's assessment of the relative importance of quality of life compared with length of life. Patients should be assisted in reviewing and revising their life priorities, resolving their unfinished business, and putting their financial and personal affairs in order.

Dying patients may wish to prepare for death and to help prepare family members to go on without them. Both patients and families benefit from education on the dying process. Families should be guided through their anticipatory grief, and arrangements should be made to ensure that the patient's and family's needs and goals regarding the dying process are respected. Planning to ensure continuing care and referrals to appropriate care is important. Arrangements should be available to ensure that the patient does not die alone unless that is the patient's preference.

Clinicians should discuss the prognosis with patients and their families clearly and consistently to help them develop realistic expectations. Information about the natural history of the specific tumor and the realistic outcomes of anticancer therapy should be included in the discussion. Many investigators have shown that seriously ill middle-aged and older patients tend to be more optimistic and less accurate about their prognosis than their physicians; such misunderstanding of the situation can affect their preferences for cardiopulmonary resuscitation and for life-extending measures.¹⁰⁸

Spiritual, existential, and cultural issues are often best addressed through collaboration with pastoral care counselors, professional translators, the patient's personal clergy, and representatives from the patient's cultural community. Religious and cultural issues surrounding the beliefs and practices near the time of death must be anticipated and carefully managed.¹⁰⁹ Finally, social and spiritual support and resource management interventions should be provided to ensure a safe end-of-life care environment, a competent primary caregiver, and access to necessary medications and treatments. Providers must be sensitive to cultural values that may influence the best way for this information to be presented and discussed.

Palliative care interventions for managing specific symptoms and the benefits and risks of anticancer therapy are discussed below as outlined in the algorithms. Additional palliative care interventions for other symptoms will be developed as deemed necessary.

Anticancer Therapy

A recent Institute of Medicine (IOM) report, *Communicating with Patients on Health Care Evidence*, found that 90% of Americans surveyed want to know their options for tests and treatments and to be involved in decision making for their health, with almost 50% wanting to discuss the option of doing nothing.^{110,111} However, the report also found that far fewer respondents had such discussions with their physicians.

Patients who have years to months to live and a good performance status are likely to be interested in continuing anticancer therapy to prolong survival and reduce cancer-related symptoms.¹¹²⁻¹¹⁵ Anticancer therapy may be conventional evidence-based treatment as outlined in the NCCN disease-specific guidelines (available at www.NCCN.org) or treatment in the context of a clinical trial. In some of the advanced-stage cancers, chemotherapy may be superior to best supportive care and

may prolong survival.^{116,117} Furthermore, patients with advanced non-small cell lung cancer who are not eligible for systemic chemotherapy may benefit from targeted therapies that are effective for relieving symptoms, maintaining stable disease, and improving quality of life without the adverse events that may be associated with cytotoxic cancer therapies.¹¹⁸ Physicians, patients, and their families should discuss intent, goals, and range of choices; benefits and risks of anticancer therapy; and possible effects on quality of life. In addition, the oncology team should prepare the patient psychologically for possible disease progression.

Anticancer therapy may at times go beyond what is evidence-based. Interestingly, data from a CanCORS study of 1574 patients with metastatic non-small cell lung cancer suggested that many patients received higher doses and a greater number of palliative radiation treatments than what is supported by current evidence.¹¹⁹ Additionally, a study of patients with metastatic colorectal cancer revealed that over 90% of patients consulted with a medical oncologist, and 82% of these patients received chemotherapy.¹²⁰

Patients with months to weeks to live should be provided with guidance regarding the anticipated course of the disease. Physicians should reassess patient's understanding of goals of therapy and preferences regarding prognostic information. These patients are typically tired of therapy, homebound, and more concerned about the side effects of more treatment. The focus of treatment for these patients shifts from prolonging life towards maintaining quality of life. These patients should consider potential discontinuation of anticancer treatment and be offered best supportive care, including referral to palliative care or hospice.^{121,122} To avoid demeaning the value of end-of-life care, palliative care should not be described as "just hospice."

In general, patients with weeks to days to live (ie, dying patients) should not be given anticancer therapy, but should be given intensive palliative care focusing on symptom control and preparation for the dying process.

Symptom Management

Special considerations in the implementation of these guidelines based on life expectancy are delineated in the algorithms. The major focus of these special considerations is the withholding and withdrawal of aggressive interventions; prevention and elimination of side effects associated with pharmacologic pain management; the acceptance of loss of function for the sake of relief of symptoms; and the treatment of the unique symptoms of patients in their final hours of life.

With regard to symptoms, the control of pain, dyspnea, anorexia/cachexia, nausea and vomiting, constipation, malignant bowel obstruction, fatigue, delirium, and psychological distress is fundamental¹²³⁻¹²⁵ and discussed in detail below. As a general principle, if/when appropriate, providers should try to use palliative interventions that may address multiple symptoms.

Pain

See the [NCCN Guidelines for Adult Cancer Pain](#). In addition, it is important to note that dying patients in their last weeks of life have several specific requirements. For instance, opioid dose should not be reduced solely for decreased blood pressure, respiration rate, or level of consciousness. In fact, opioids can be titrated aggressively for moderate/severe acute/chronic pain.¹²⁶ In addition, palliative sedation can be considered for refractory pain (see below) following consultation with pain management/palliative care specialists.

**Dyspnea**

Dyspnea is one of the most common symptoms in patients with advanced lung cancer.¹²⁷ The American Thoracic Society consensus statement defines dyspnea as “a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity.”¹²⁸

Symptom intensity should first be assessed in all patients. Symptom intensity in non-communicative patients with weeks to days to live should be assessed using other distress markers of dyspnea. Next, underlying causes or comorbid conditions should then be treated using chemotherapy or radiation therapy; therapeutic procedures for cardiac, pleural, or abdominal fluid¹²⁹⁻¹³¹; bronchoscopic therapy; or bronchodilators, diuretics, steroids, antibiotics, transfusions, or anticoagulants for pulmonary emboli.

Both pharmacologic and non-pharmacologic interventions have been assessed for management of dyspnea. A recent review concluded that little definitive data evaluating the effectiveness of dyspnea interventions exist and that randomized controlled trials are needed.¹³² Other reviews have determined that there are sufficient data to make treatment recommendations.^{130,133} Pharmacologic interventions may include opioids with or without benzodiazepines.^{130,134-139} Benzodiazepines can be tried for treatment of dyspnea if it is associated with anxiety; the beneficial effect of benzodiazepines on dyspnea in patients with advanced cancer is small.¹³⁹

Of the opioids, morphine has undergone the most extensive investigation for treating dyspnea in patient with cancer, but recent studies have also assessed opioids such as fentanyl and oxycodone. A single-institution trial of nebulized fentanyl in patients with cancer with dyspnea showed improved oxygenation and reduced tachypnea, and

79% of patients said it improved their breathing.¹⁴⁰ An attempted randomized placebo-controlled trial at the same institution was not successful, because the practice had already diffused widely with over 1000 doses being prescribed.¹⁴¹ Multiple case reports give promising data about fentanyl, but further placebo-controlled trials are needed.¹⁴² In a small randomized controlled trial, prophylactic subcutaneous fentanyl was effective for improving dyspnea and fatigue at rest and following a 6-minute walk test.¹⁴³ A study revealed that nebulized fentanyl reduced intensity and unpleasantness of dyspnea in patients with chronic obstructive pulmonary disease (COPD).¹⁴⁴ Nebulized fentanyl has not yet been studied in patients with cancer, but it can be considered in patients who do not respond well to the other interventions in these guidelines. Additionally, an observational study of 136 patients with terminal cancer also suggested that continuous infusion of subcutaneous oxycodone may provide relief of dyspnea in addition to relief of pain.¹⁴⁵

Scopolamine, atropine, hyoscyamine, and glycopyrrolate are options to reduce excessive secretions associated with dyspnea.¹⁴⁶⁻¹⁵⁰ Glycopyrrolate does not effectively cross the blood brain barrier,¹⁵¹ and thus is less likely than the other drug options to cause delirium.^{152,153} Scopolamine can be administered subcutaneously or transdermally; physicians should be aware that the onset of benefit for transdermal scopolamine patches is about 12 hours,¹⁵⁴ and they are thus not an appropriate choice for imminently dying patients. A subcutaneous injection of scopolamine can be administered when the patch is applied or if control of secretions is inadequate. Non-pharmacologic interventions include the use of handheld fans directed at the face. A randomized, controlled, crossover trial demonstrated that breathlessness was reduced in patients when they directed a handheld fan toward their faces.¹⁵⁵ A time-limited trial of mechanical ventilation, as

clinically indicated, and/or oxygen therapy for hypoxia may also be beneficial. In a recent feasibility study of 200 patients with solid tumors randomized to receive either noninvasive positive-pressure ventilation (biphasic positive airway pressure, BiPAP) or oxygen therapy, patients in the ventilation group had greater improvements in dyspnea symptoms and required lower doses of opiates than patients in the oxygen group.¹⁵⁶ However, a smaller phase II randomized trial comparing high-flow oxygen to BiPAP for persistent dyspnea in patients with advanced cancer revealed no significant differences between the two approaches.¹⁵⁷ As life expectancy decreases, the role of mechanical ventilation and oxygen diminishes, and the role of opioids, benzodiazepines, glycopyrrolate, and scopolamine increases. If fluid overload is a contributing factor, enteral and parenteral fluids should be decreased or discontinued, and low-dose diuretics can be considered.

Anorexia/Cachexia

Cachexia is physical wasting with loss of skeletal and visceral muscle mass and is very common among patients with cancer.^{158,159} Many patients with cancer lose the desire to eat (anorexia), which contributes to cachexia. Cachexia can also occur independently from anorexia, as proinflammatory cytokines and tumor-derived factors directly lead to muscle proteolysis.^{158,159} Cachexia leads to asthenia (weakness), hypoalbuminemia, emaciation, immune system impairment, metabolic dysfunction, and autonomic failure. Cancer-related cachexia has also been associated with failure of anti-cancer treatment, increased treatment toxicity, delayed treatment initiation, early treatment termination, shorter survival, and psychosocial distress.¹⁵⁸⁻¹⁶⁰ A recent study that examined cancer cachexia in a cohort of 1473 patients across all weight ranges showed that muscle depletion conveys a

similarly poor prognosis as involuntary weight loss, regardless of body mass index.¹⁶¹

Treatment includes the relief of symptoms that interfere with food intake (eg, depression, pain, constipation, nausea/vomiting), metoclopramide for early satiety, and the use of appetite stimulants (megestrol acetate or prednisone) when increased appetite is an important aspect of quality of life.^{130,133,162-164} A recent systematic review and meta-analysis of megestrol acetate revealed improved appetite and slight improvements in weight gain when using this drug to treat anorexia/cachexia in patients with cancer.¹⁶³ However, the panel cautions that megestrol acetate increases the risk of blood clots and edema, and death occurs in 1 in every 23 patients taking this drug.¹⁶³

A combination therapy approach may yield the best possible outcomes for patients with cancer cachexia. A randomized phase III trial in 332 patients with cancer-related anorexia/cachexia revealed superior outcomes for patients receiving a combination regimen that included medroxyprogesterone, megestrol acetate, eicosapentaenoic acid and L-carnitine supplementation, and thalidomide, versus therapy with any of the above single agents.¹⁶⁵ Another phase III trial of 104 patients with advanced gynecologic cancers and cachexia supported the merits of combination therapy; compared with megestrol acetate alone, patients receiving megestrol acetate plus L-carnitine, celecoxib, and antioxidants had improved lean body mass, appetite, and quality of life.¹⁶⁶

Although cannabinoid-based interventions (eg, dronabinol, cannabis) have some demonstrated efficacy for treating chemotherapy-induced nausea and vomiting and AIDS-related anorexia, the data to support cannabinoid-based interventions for treating anorexia/cachexia in patients with cancer are very limited.¹⁶⁷ A randomized clinical trial of cannabis extract and delta-9-tetrahydrocannabinol in patients with

cancer-related anorexia-cachexia syndrome did not demonstrate a benefit of these agents over placebo on appetite and quality of life.¹⁶⁸ Another randomized trial comparing megestrol acetate to dronabinol in treating cancer-associated anorexia revealed megestrol acetate to be superior for promoting weight gain (75% vs. 49% of patients) and appetite (11% vs. 3%) in patients with advanced cancer.¹⁶⁹ However, to a lesser extent, dronabinol did improve appetite and weight gain in some study patients. Ultimately, for some patients with cancer-related anorexia, cannabinoids could be helpful. However, it is important to note that cannabinoid administration in elderly patients may induce delirium, and providers should be aware of the local state rules and regulations regarding medicinal cannabinoid use.

Nutrition consultation should also be considered, because calorie-dense, high-protein supplementation has demonstrated some efficacy for weight stabilization,^{130,158,170-172} although some studies show nutritional interventions to be ineffective.¹⁷³ A meta-analysis found that while nutritional intervention does not significantly affect weight gain or energy intake, it can improve some aspects of quality of life, including emotional functioning, dyspnea, and hunger.¹⁷⁴ Nutritional support, including enteral and parenteral feeding as appropriate, should also be considered when the disease or treatment affects the ability to eat and/or absorb nutrients and the patient's life expectancy is months to years.¹⁷⁵ The goals and intensity of nutritional support change as life expectancy is reduced to weeks to days. Overly aggressive enteral or parenteral nutrition therapies can actually increase the suffering of dying patients.¹⁷⁵⁻¹⁷⁸ In addition, a recent randomized controlled trial of patients with cancer enrolled in hospice found that parenteral hydration had no effect on dehydration symptoms such as fatigue and hallucination and had no effect on quality of life or survival.¹⁷⁹ Therefore, instead of artificial hydration and nutrition, palliative care in the final weeks of life

focuses on treating dry mouth and thirst, and providing education and support to the patient and family regarding the emotional aspects of withdrawal of nutritional support. Family members should be informed of alternate ways to care for dying patients.

Nausea and Vomiting

Chemotherapy-induced nausea and vomiting has a major impact on a patient's quality of life.¹⁸⁰ Nausea and vomiting induced by chemotherapy or radiation therapy should be managed as outlined in the [NCCN Guidelines for Antiemesis](#). Patients can also experience nausea and vomiting unrelated to chemotherapy and radiation, resulting from gastric outlet obstruction, bowel obstruction, constipation, opioid use, or hypercalcemia.¹⁸¹ These causes should be identified and treated. Proton pump inhibitors and histamine-2 (H2) receptor antagonists can be used to manage gastritis or gastroesophageal reflux. Gastric outlet obstruction may benefit from treatment with corticosteroids; alternative treatment options include endoscopic stenting or insertion of a decompressing G-tube. Many medications can also cause nausea and vomiting, and blood levels of possible culprits, such as digoxin, phenytoin, carbamazepine, and tricyclic antidepressants, should be checked.^{182,183}

Non-specific nausea and vomiting can be managed with dopamine receptor antagonists (eg, prochlorperazine, haloperidol, metoclopramide, olanzapine) or benzodiazepines (anxiety-related nausea). Persistent nausea and vomiting can be treated by titrating dopamine receptor antagonists to maximum benefit and tolerance.¹⁸⁴⁻¹⁸⁸ For persistent nausea, adding 5-HT₃ (5-hydroxytryptamine 3) receptor antagonists^{189,190} and/or anticholinergic agents and/or antihistamines,¹⁹¹ corticosteroids,^{191,192} continuous or subcutaneous infusion of antiemetics, antipsychotics (eg, olanzapine or haloperidol),¹⁹³ and/or cannabinoids can also be considered.¹⁹⁴ Opioid rotation may also help

alleviate symptoms.¹⁹⁵ Agents that target the cannabinoid system may offer some efficacy in treating refractory chemotherapy-induced nausea and vomiting.¹⁹⁶ Dronabinol and nabilone are two cannabinoid agents approved for treating chemotherapy-induced nausea and vomiting that is refractory to standard antiemetic therapies. Alternative therapies (eg, acupuncture, hypnosis, cognitive behavioral therapy) can also be considered.¹⁹⁷⁻¹⁹⁹ Palliative sedation (see below) can be considered as a last resort if intensified efforts by specialized palliative care or hospice services fail.

A systematic review assessed the level of evidence for antiemesis unrelated to chemotherapy.²⁰⁰ While the authors concluded that antiemetic recommendations have moderate to weak evidence at best, the strongest evidence supports the use of metoclopramide; studies of multidrug combination therapies do not support their effectiveness.

Constipation

Constipation occurs in approximately 50% of patients with advanced cancer and most patients treated with opioids.²⁰¹ Although several drugs including antacids, anticholinergic drugs (antidepressants, antispasmodics, phenothiazines, and haloperidol), and antiemetics are known to cause constipation,²⁰² opioid analgesics are most commonly associated with constipation. In addition to physical discomfort, constipation in patients with advanced cancer can cause psychological distress and anxiety regarding continued opioid use.²⁰³ Opioid-induced constipation should be anticipated and treated prophylactically with a stimulating laxative to increase bowel motility with or without stool softeners.²⁰⁴ While there is little evidence on which is the best initial bowel regimen in patients with cancer, one small study compared the use of senna alone versus a senna-docusate combination. The results demonstrated that the addition of the stool softener docusate was not

necessary.²⁰⁵ Increasing fluid intake, dietary fiber, and physical activity should also be encouraged, when appropriate.

If constipation is present, the cause and severity must be assessed. Impaction, obstruction, and other treatable causes, such as hypercalcemia, hypokalemia, hypothyroidism, and diabetes mellitus, should be assessed and treated. Constipation may also be treated by adding bisacodyl 10 to 15 mg, 2 to 3 times daily with a goal of 1 non-forced bowel movement every 1 to 2 days. If impaction is observed, glycerine suppositories may be administered or manual disimpaction performed.

If constipation persists, adding other laxatives may be considered, such as rectal bisacodyl once daily or oral polyethylene glycol, lactulose, magnesium hydroxide, or magnesium citrate. If gastroparesis is suspected, the addition of a prokinetic agent, such as metoclopramide, may be considered. Recent studies have shown that methylnaltrexone, a peripherally acting antagonist of μ -opioid receptors, helps relieve opioid-induced constipation while maintaining pain control.^{206,207} Based on these results, the NCCN Palliative Care Panel recommends considering 0.15 mg per kilogram of body weight of methylnaltrexone every other day (no more than once a day) for patients experiencing constipation that has not responded to standard laxative therapy. Methylnaltrexone should not be used in patients with a postoperative ileus or mechanical bowel obstruction.

Malignant Bowel Obstruction

Malignant bowel obstructions are usually diagnosed clinically and confirmed with radiography. For patients with years to months to live, surgery following CT scan is the primary treatment option. While surgery can lead to improvements in quality of life, surgical risks should be discussed with patients and families. Although surgery is the primary

treatment for malignant obstruction, some patients with advanced disease or patients in generally poor condition are unfit for surgery and require alternative management to relieve distressing symptoms. Risk factors for poor surgical outcome include ascites, carcinomatosis, palpable intra-abdominal masses, multiple bowel obstructions, previous abdominal radiation, advanced disease, and poor overall clinical status.²⁰⁸ In these patients, medical management can include pharmacologic measures, parenteral fluids, endoscopic management, and enteral tube drainage.

Pharmacologic management of malignant bowel obstruction can be separated into two groups of patients: those for whom the goal is to maintain gut function and those for whom gut function is no longer possible. When the goal is maintaining gut function, patients can be treated with opioids, antiemetics, and corticosteroids, alone or in combination. When gut function is no longer considered possible, pharmacologic options also include somatostatin analogs (eg, octreotide) and/or anticholinergics.²⁰⁹⁻²¹³ Antiemetics that increase gastrointestinal mobility such as metoclopramide should not be used in patients with complete obstruction, but may be beneficial when obstruction is partial. Use of octreotide is recommended early in the diagnosis because of its efficacy and tolerability.^{214,215} Despite positive findings from several smaller randomized trials, a recent phase III trial of octreotide in 86 patients with malignant bowel obstruction failed to demonstrate a significant effect of this drug on days free of vomiting, number of vomiting episodes, symptom control, and other secondary endpoints.²¹⁶

A venting gastrostomy tube (inserted by interventional radiology, endoscopy, or surgery), a percutaneous endoscopic gastrostomy tube, or an endoscopically placed stent can also palliate symptoms of malignant bowel obstruction.^{217,218} Total parenteral nutrition can be

considered to improve quality of life in patients with a life expectancy of years to months. These interventions have been shown to have little positive impact on survival time, but may improve quality of life.^{101,102}

Fatigue/Weakness/Asthenia

The data on methylphenidate for treating cancer-related fatigue have been mixed. While some trials have suggested a dose-dependent benefit of this agent on fatigue symptoms,^{245,246} other studies have failed to produce positive results.²⁴⁷ Phase III randomized trials of modafinil for treating cancer-related fatigue suggested that modafinil had a modest efficacy and was most effective for those with severe fatigue.^{248,249} For more information, see [NCCN Guidelines for Cancer-Related Fatigue](#).

Sleep/Wake Disturbances

Patients with cancer often suffer from insomnia or daytime sedation.²¹⁹⁻²²¹ In a recent study of 442 patients with advanced cancer, 330 (75%) patients were assessed as having baseline sleep disturbance as assessed by the Edmonton Symptom Assessment System (ESAS) sleep item.²²² Patients should first be evaluated for sleep/wake disturbances using, for example, the Epworth Sleepiness Scale.²²³ If patients have a history of sleep-disordered breathing (eg, excessive snoring, gasping for air, observed apneas, frequent arousals, sudden involuntary movement of arm or legs during sleep, unexplained daytime drowsiness), polysomnography should be considered. Polysomnography should also be considered for patients with head and neck cancers, because obstructive sleep apnea (OSA) is prevalent in patients with this disease.^{224,225} Primary sleep disorders, such as OSA and periodic limb movement disorder, should be treated with continuous positive airway pressure (CPAP) or BiPAP.²²⁶ Restless leg syndrome, if present, can be treated with ropinirole, pramipexole, or carbidopa-levodopa.²²⁷⁻²³⁴ Fears and anxiety regarding death and disease should be explored, and other contributing factors to sleep/wake disturbances



should be treated, including pain, depression, anxiety, delirium, and nausea. Cognitive behavioral therapy may be effective in treating sleep/wake disturbances in patients with cancer.^{133,235-239}

For refractory insomnia, pharmacologic management includes the short-acting benzodiazepine lorazepam, the non-benzodiazepine zolpidem, and sedating antidepressants such as trazodone and mirtazapine.²⁴⁰ The panel suggests that mirtazapine may be especially effective in patients with depression and anorexia. Benzodiazepines should be avoided in older patients and in patients with cognitive impairment, because they have been shown to cause decreased cognitive performance.²⁴¹ Caution should be exercised when administering zolpidem due to the known risk of next-morning impairment. In 2013, the U.S. Food and Drug Administration required lower recommended doses of zolpidem (ie, from 10 mg to 5 mg for immediate-release products from 12.5 mg to 6.25 mg for extended-release formulations).²⁴²

For refractory daytime sedation, the guidelines suggest several options. The central nervous system stimulants methylphenidate or dextroamphetamine should be given with a starting dose of 2.5 to 5 mg orally (PO) with breakfast. If the effect of the drug does not last through lunch, a second dose can be given at lunch, preferably no later than 2:00 PM. Doses can be escalated as needed.²⁴³ Another option for refractory daytime sedation is the psychostimulant modafinil, which has been approved in adults for excessive sleepiness associated with OSA/hypopnea syndrome (OSAHS), shift work sleep disorder, and narcolepsy.²⁴⁴ The panel also recommends caffeine and dextroamphetamine as additional options for refractory daytime sedation. The last dose of caffeine should be given no later than 4:00 PM.

Dying patients should be assessed for their desire to have their insomnia or sedation treated. The doses of their pharmacologic therapies can be adjusted as appropriate. The addition of an anti-psychotic drug (chlorpromazine or quetiapine) can be considered in patients whose insomnia is refractory.

Please also see the [NCCN Guidelines for Adult Cancer Pain](#) and the [NCCN Guidelines for Cancer-Related Fatigue](#) for their discussions on sleep/wake disturbances.

Delirium

Delirium should be assessed using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.²⁵⁰ Reversible causes should be identified and treated appropriately.²⁵¹ Delirium presents as hypoactive or hyperactive subtypes that may require different approaches to management.²⁵² A recent systematic review suggested that hypoactive delirium was the most prevalent subtype in palliative care patients and that this condition is often underdiagnosed due to its presentation.²⁵³

Two comprehensive reviews describe the evidence base for recommended pharmacologic and non-pharmacologic treatments for delirium in patients with cancer.^{133,254} Non-pharmacologic interventions (eg, reorientation, cognitive stimulation, sleep hygiene) should be maximized before pharmacologic interventions are used. Delirium-inducing medications (ie, steroids, anticholinergics) should be reduced or eliminated as much as possible. Benzodiazepines should not be used as initial treatment for delirium in patients not already taking them. The symptoms of moderate delirium can be controlled with oral haloperidol, risperidone, olanzapine, or quetiapine fumarate.²⁵⁵⁻²⁵⁷ The symptoms of severe delirium (ie, agitation) should be controlled with antipsychotic, neuroleptic drugs such as haloperidol, olanzapine, or

chlorpromazine.²⁵⁸ Because of its hypotensive side effect, intravenous chlorpromazine should only be used in bed-bound patients. A benzodiazepine, such as lorazepam, may be added for agitation that is refractory to high doses of neuroleptics.²⁵⁹ The presence of therapeutic levels of neuroleptics usually prevents the paradoxical excitation sometimes seen when delirious patients are given lorazepam. The dosages of these symptom-control medications should be titrated to optimal relief. Opioid dose reduction or rotation can also be considered for patients with severe delirium. Caregivers should be supported in caring for their loved one and coping with this distressing condition.

Delirium in patients with advanced cancer and limited life expectancy may shorten prognosis.²⁶⁰ In these patients, iatrogenic causes should be eliminated whenever possible. Opioid rotation can be considered (see [NCCN Guidelines for Adult Cancer Pain](#)) if the delirium is believed to be caused by neurotoxicity of the current opioid. If delirium is a result of disease progression, palliative care must be focused on symptom control and family support. Neuroleptic and benzodiazepine medications should have their dose increased and/or their route of administration changed to ensure adequate delirium symptom control.²⁶¹ Unnecessary medications and tubes should be removed. For refractory delirium in dying patients, palliative sedation can be considered following consultation with a palliative care specialist and/or psychiatrist (see below).

Please also see the [NCCN Guidelines for Distress Management](#) for further discussion of delirium in patients with cancer.

Psychosocial Distress – Social Support/Resource Management

For distress related to psychological or psychiatric complications and spiritual or existential crisis, please see the [NCCN Guidelines for Distress Management](#).

For best outcomes, psychosocial care should be integrated into routine cancer care across all disease stages and in both the inpatient and outpatient settings.^{47,262} A recent systematic review of patients with advanced cancer identified psychosocial resources among the factors that promoted personal growth during the experience of cancer.²⁶³

For patients with estimated life expectancy ranging from years to months experiencing psychosocial distress, social support/resource management should be offered. Patients should be cared for in a safe environment with available caregivers. In addition, it is important to ensure that the patient has adequate financial resources and to refer to social services as needed. Support and education should be provided to the caregivers and family members.²⁶⁴ Personal, spiritual, or cultural issues related to the patient's illness and prognosis should be discussed. Bereavement risk should be assessed. If language is a barrier, a professional health care interpreter, who is not related to the patient or family, should be available for patients, caregivers, and families as needed.

In a dying patient with an estimated life expectancy of weeks to days, the patient's desires for comfort should be evaluated and supported. The process of dying and the expected events should be explained to the patient, caregivers, and family members. For children of parents with cancer, a survey-based study demonstrated that receiving end-of-life information enhanced trust in the care provided to their parents.⁸⁸ Bereavement risk should be reassessed. Patients and family members should be provided with emotional support to address any intra-family conflict regarding palliative care interventions. Eligibility and readiness for specialized palliative/hospice care should be determined.

Advance Care Planning

The oncology team should initiate discussions of personal values and preferences for end-of-life care while patients have a life expectancy of years to months. Recent studies have shown that these discussions frequently happen too late in the trajectory of disease, often during acute hospital care and often with health professionals other than the primary oncologist.²⁶⁵⁻²⁶⁷ Further, earlier end-of-life care discussions have been associated with less aggressive care and increased use of hospice,^{268,269} while less aggressive care has been associated with an improved quality of life.²⁷⁰ Studies suggest that most patients with cancer would prefer to die at home,^{271,272} but lack of timely advance care planning can render this impossible.

ASCO has developed a booklet to help patients and their families understand and discuss the cancer diagnosis and treatment options (<http://www.cancer.net/coping/advanced-cancer-care-planning>). A recent randomized controlled trial found that a video decision support tool increased the likelihood that patients would choose to forgo resuscitation.²⁷³ A randomized controlled trial of a structured intervention to facilitate end-of-life discussions (consisting of an information pamphlet and provider discussion) led to earlier designation of do-not-resuscitate orders and decreased the likelihood of patients dying in the hospital.²⁷⁴ In addition, a recent study showed that electronic prompts and email reminders to doctors could increase rates of documentation of code status in patients with advanced lung cancer.²⁷⁵

Advance care planning should include an open discussion about palliative care options, such as hospice; personal values and preferences for end-of-life care; the congruence between the patient's wishes/expectations and those of the family/health care team; and

information about advance directives. Patients should be asked if they have completed any advance care planning such as living wills, powers of attorney, or delineation of specific limitations regarding life-sustaining treatments including cardiopulmonary resuscitation, mechanical ventilation, and artificial nutrition/hydration. The patient's values and preferences and any decisions should be documented in the medical record, including MOLST or POLST (Medical Orders for Life-Sustaining Treatment or Physician Orders for Life-Sustaining Treatment) if completed.

When the patient's life expectancy is reduced to months to weeks, the oncology team should actively facilitate completion of appropriate advance directives and ensure their availability in all care settings. MOLST/POLST should be documented and accessible to all providers across care settings. The team should also confirm the patient's values and decisions in light of changes in status. Palliative care consultation can be considered to assist in conflict resolution when the patient, family, and/or medical professional team do not agree on the benefit/efficacy of interventions.

Where the patient wants to die should be determined. Most patients with cancer would prefer to die at home,^{271,272} but sometimes their care needs or support system at home cannot support their care. Some patients request to receive end-of-life care in a skilled nursing facility or an in-patient hospice facility.^{272,276} A prospective study showed that patients dying in an ICU had higher levels of physical and emotional distress compared with patients dying at home or in hospice. Additionally, caregivers of these patients had a greater incidence of prolonged grief disorder.²⁷⁷ Providing palliative care services has been shown to decrease deaths in ICUs.²⁷⁶ A recent retrospective cohort study showed that patients who wanted to die at home were more likely to do so if they had daily hospice visits, if they were married, if they had

advance directives, if they did not have moderate or severe pain, or if they had good performance status.²⁷² A second retrospective study suggested that referral to specialist palliative care at a greater interval of time prior to death increased the likelihood of patient's dying at home or in hospice rather than in the hospital.²⁷⁸ If advance care plans have not been completed, the oncology team should explore the patient's reluctance to engage in advance care planning and refer to palliative care if needed.

In patients with a life expectancy of only weeks to days, the patient's decision regarding cardiopulmonary resuscitation and other life-sustaining treatments must be clarified and confirmed. The desire for organ donation and/or autopsy must also be explored with the patient. Overall, the oncology team must implement and ensure compliance with the patient's advance care plan.

Palliative Care Reassessment

The outcome measures for these guidelines are much more difficult to define than those for NCCN disease-specific guidelines. The panel reviewed end-of-life care outcomes from several surveys of North American citizens.^{66,279-281} The panel chose a modified version of Singer's outcomes until more precise outcome measures are available. Acceptable palliative care should provide the following: 1) adequate pain and symptom management; 2) reduction of patient and family distress; 3) acceptable sense of control; 4) relief of caregiver burden; 5) strengthened relationships; and 6) optimized quality of life, personal growth, and enhanced meaning. The panel added "having an advance care plan in progress" as part of the criteria for acceptable outcome. Research is ongoing regarding better ways to measure "dying well."²⁸²

All patients should be reassessed regularly, and effective communication and information sharing must exist between the patient,

caregivers, and health care providers. Patients and family members benefit most from ongoing discussions about the natural history of the disease and prognosis in clear, consistent language. If the interventions are unacceptable upon reassessment, the oncology or palliative care team should intensify palliative care and reassess the patient and family situation. The oncology team should also consult specialized palliative care services, hospice, or an ethics committee. Referral to a psychiatrist or psychologist to evaluate and treat undiagnosed psychiatric disorders, substance abuse, and inadequate coping mechanisms should be considered. If psychosocial distress persists, palliative care options should be intensified, and the patients should be managed according to the NCCN Guidelines for Distress Management.

Patients' treatment goals and expectations may change and evolve as disease progresses. Reassessment should be ongoing, with continuation or modification of life-expectancy-guided palliative care until the patient's death or survivorship.

Special Palliative Care Interventions

Requests for Hastened Death

Special palliative care interventions include responses to requests for hastened death (ie, physician aid-in-dying, physician-assisted suicide, euthanasia). The most appropriate response to a request for assisted suicide is to intensify palliative care. All such patients should be referred to a palliative care specialist. A request for hastened death often has important meanings that require exploration. Clarifying these meanings can sometimes enlarge the range of useful therapeutic options instead of providing a lethal prescription. Open exploration of the patient's request for aid in dying can often identify unmet needs and new palliative care interventions that may be helpful. Alternatives to physician-assisted suicide, such as withdrawal of life-sustaining

treatment, voluntary cessation of eating and drinking, and/or sedation, should be considered and discussed with patients and families. Psychiatric consultation to diagnose and treat reversible causes of psychological suffering should be requested. Patients should be assured that their health care team is committed to providing continuing care. Although physician-assisted suicide, under specified conditions, is legal in the states of Oregon, Montana, Vermont, and Washington, euthanasia is not legal in any of the United States.²⁸³⁻²⁸⁶ It is important for physicians to know the local legal status of hastened death, as other states have pending legislation regarding either prohibiting or permitting physician-assisted suicide.

Palliative Sedation

Palliative sedation can be an effective symptom-control treatment for imminently dying patients with refractory symptoms and a life expectancy of hours to days. Informed consent must be obtained from the patient and/or a surrogate or family member following discussions that clarify patient's disease status, treatment goals, prognosis, and expected outcomes. Clinicians may find that applying usual benefit/risk analysis to this type of intervention will suffice in medical decision-making. Palliative sedation has its ethical justification in the Doctrine of Double Effect,²⁸⁷⁻²⁹² which means that the possible harm (possible respiratory depression, starvation, and hastened death) that may come as a side effect of doing good (relieving intolerable suffering) is justified. Furthermore, results from a study that prospectively matched terminally ill patients with cancer receiving or not receiving palliative sedation suggest that sedation does not, in fact, shorten life.²⁹³ Similar results were obtained from a recent systematic review of 10 retrospective or prospective nonrandomized studies, although the overall quality of studies was quite poor.²⁹⁴ An ethics consult may be considered in accordance with institutional guidelines and state regulations.

Palliative sedation is best performed by palliative care experts. The most common sedatives used for palliative sedation are thiopental, pentobarbital, and midazolam by parenteral infusions.²⁹⁰ Infusional lorazepam, amobarbital, and propofol may also be used.^{290,295} Recent studies suggested that palliative sedation may also be feasible in the home setting and could be utilized in patients who wish to die at home.^{296,297}

Care of the Imminently Dying Patient

An imminently dying patient is defined as one within hours of death who is not stable enough for transport. Caring for an imminently dying patient is intense for the patient, family, and health care team. A recent international qualitative study described many of the common non-pharmacologic palliative care activities provided in the last days of life.²⁹⁸ An end-of-life care order set that includes physical, practical, and psychosocial interventions may be beneficial for practitioners to use for imminently dying patients.

The physical aspects of care for an imminently dying patient focus on adequate symptom management and comfort, keeping in mind the patient's wishes and values. Approaches may include intensifying ongoing care; adjusting medication doses for optimal comfort; discontinuing unnecessary interventions (eg, diagnostic tests, transfusions, artificial nutrition, hydration, dialysis, needle sticks); ensuring access to symptom-relief medication through alternate routes if oral administration is difficult; providing physical comfort by providing a pressure-relieving mattress and regular repositioning; treating urinary retention and fecal impaction; deactivation of implanted defibrillator; controlling terminal restlessness and agitation with palliative sedation; reducing death rattle/terminal secretion (eg, repositioning patient; reducing parenteral and enteral fluids; adding medications such as

scopolamine, hyoscyamine, atropine, or glycopyrrolate)¹⁵⁰; and preparing for patient and family requests for autopsy and/or organ donation.

The psychosocial aspects of care for an imminently dying patient take into account individual and family goals, preferences, cultures, and religious beliefs. The care plan may include consultation with social workers or chaplains to meet social and spiritual needs; open communication between the patient, family, and care team regarding the physical and psychological aspects of the dying process and the importance of honoring any advance directives; and anticipatory grief counseling to help facilitate caregiver closure. Patients who are actively dying in their final hours of life should be allowed to spend uninterrupted time with family.

The practical aspects of care for an imminently dying patient in the hospital include: mobilizing in-hospital end-of-life care policy and procedures; ensuring that the patient's advance directive is documented and implemented and a do-not-attempt-resuscitation (DNAR) or allow natural death (AND) order is written and followed; securing a private room for the patient; and enabling family presence around-the-clock. If the patient and family have not documented a DNAR order, patient/family education and counseling should be intensified to try to help them accept this level of care to prevent harm to the patient from futile attempts at cardiopulmonary resuscitation. Providers should be aware that policies regarding resuscitation may differ based on treatment setting. A patient with a documented inpatient DNAR order may also require DNAR orders for out-of-hospital settings (eg, residential care, ambulance transport). In states where the MOLST/POLST is honored across all treatment settings, it will protect the patient.

A Peaceful Death

These NCCN Guidelines are the first to include death as an expected outcome and after-death care for the family as an essential part of the continuum of cancer care. Many studies have attempted to define a “good death” or a “peaceful death” from the perspective of clinicians, patients, and families.²⁹⁹⁻³⁰² Interestingly, one study found that patients, families, and physicians had very similar ideas of what constitutes a peaceful death: freedom from pain, being at spiritual peace, and being with family ranking among the top three considerations by all three groups.³⁰² End-of-life care should be flexible enough to ensure that the death is viewed as a peaceful death by those involved.³⁰² The definition of a “peaceful death” used by the NCCN Palliative Care Panel is “one that is free from avoidable distress and suffering for patients, families and caregivers; in general accord with patient’s and family’s wishes; and consistent with clinical, cultural, and ethical standards.”³⁰³

Final results of the prospective, longitudinal, cohort Coping With Cancer study of 396 patients with advanced cancer and their caregivers were recently reported. The study found a higher quality of life in the last weeks of life in patients who avoided visits to the ICU and feeding tubes, did not die in the hospital, worried less, prayed or meditated, were visited by a pastor in the hospital or clinic, and felt a strong therapeutic alliance with their physicians.²⁷⁰

After-Death Care Interventions

Comprehensive palliative care for the patient’s family and caregivers continues after the patient’s death. Immediate issues include ensuring culturally sensitive and respectful treatment of the body, including removal of tubes, drains, lines, and the Foley catheter (unless an autopsy is planned); providing family time with the body; addressing concerns about organ donation or autopsy; facilitating funeral



arrangements through completion of necessary paperwork; and informing insurance companies and other health care providers of the patient's death.

Bereavement support should be offered, beginning with a personal visit or telephone call from the patient's primary oncology team, followed by a condolence letter. Family members at risk for complicated bereavement or prolonged grief disorder should be identified, and complicated grief should be treated.³⁰⁴⁻³⁰⁶ Children of patients with cancer represent a uniquely at-risk population for psychosocial dysfunction. Additionally, a recent study suggested that certain predictors of prolonged grief could be identified in family caregivers at the time of the patient's entry to palliative care; these factors included pre-death symptoms of prolonged grief, spousal relationship to the patient, large impact of caring on schedule, poor family functioning, and low levels of optimism.³⁰⁷

Bereavement care is often best provided by an experienced hospice team or a skilled mental health care professional. The family may request a debriefing meeting from the medical team and may require assistance in identifying community bereavement resources. A well-supported end-of-life care experience will facilitate the family's acceptance of appropriate referrals for cancer risk assessment and risk modification. If not already recommended, providers should direct family members towards genetic screening, especially if the deceased patient was positive for known genetic markers that confer risk. For more information, see the NCCN Guidelines for [Genetic/Familial High-Risk Assessment: Breast and Ovarian](#) and [Genetic/Familial High-Risk Assessment: Colorectal](#).

Palliative Care Research

The evidence base for the treatment recommendations for physical and psychosocial symptoms in patients with cancer is generally weak.^{308,309} Clinical trials in palliative oncology face many challenges, including recruitment difficulties, high attrition rates, and insufficient funding.³¹⁰⁻³¹² Several groups have recommended considerations for the design of future palliative care clinical trials, including standardization of reporting, the integration of technology for data collection, the use of validated outcome measures, and the use of trial designs other than the randomized controlled trial.³¹³⁻³¹⁷ In addition, formal feasibility studies can help ensure the success of subsequent larger trials.^{314,318} Despite the challenges associated with conducting large-scale palliative care research studies, several notable studies have examined the impact of palliative care efforts on patient and family/caregiver outcomes (reviewed by El-Jawahri, et al.³⁰⁸).

Putting Palliative Care Guidelines into Practice

These guidelines have the goal of providing the best quality of life possible for each patient and were developed to accompany the appropriate cancer treatment guidelines. Institutions should develop processes for integrating palliative care into cancer care, both as part of usual oncology care and for patients with specialty palliative care needs. Many approaches have been described.³⁸⁻⁴⁶

Patients and families should be informed that palliative care is an integral part of their comprehensive cancer care. Educational programs should be provided to all health care professionals and trainees so that they can develop effective palliative care knowledge, skills, and attitudes. Skilled palliative care specialists and interdisciplinary palliative care teams, including board-certified palliative care physicians, advanced practice nurses, and physician assistants, should be readily



available to provide consultative or direct care to patients and families who request or require the expertise. Finally, the quality of palliative care should be monitored by institutional quality improvement programs.

The experiences of patients with cancer throughout the disease course begin with the diagnosis. Patient conditions usually move from ambulatory to sedentary as disease advances and performance status worsens. When life expectancy is a matter of days or hours, patients may become unable to communicate. These patients may be at home, living with a family member, or in a health care facility. Through understanding the patient's status relative to the natural disease trajectory and by using these guidelines, the oncology team can provide the most appropriate treatment for each patient. Oncologists and patients should discuss at the outset whether the treatment will be curative or palliative. Many palliative care questions must be considered early in each patient's comprehensive cancer care. The primary oncology team is responsible for working with patients to raise and answer these questions. Oncologists must identify patients' goals for the remainder of life to get a better sense of whether they understood and accepted the diagnosis and prognosis. Additionally, oncologists must explain the types of therapies that are available and how these therapies can affect the patient's daily life. As the cancer progresses and the value of further anticancer therapy diminishes, palliative therapy should be intensified. The issue of whether patients want more anticancer therapy must be openly addressed. The delivery of clear and consistent prognostic information can help patients make the most appropriate decisions.

Patients should be made aware that undergoing anticancer therapy does not have to sidetrack them from addressing end-of-life issues. Collaborating with palliative care experts extends oncologists' therapeutic repertoire and diminishes the stress of caring for patients

who have incurable disease. Increasing emphasis on palliative care in oncology should improve patient outcomes and provide new avenues for clinical research and professional satisfaction. Timely introduction of members of the institutional or community palliative care team allows patients to meet the individuals who will help them and their families through their experience. Because the diagnosis of cancer and impending death is such a frightening experience, oncologists must try to alleviate those fears by assuring patients that the members of a team will work with them and their families to make things less burdensome. Additionally, oncologists must discuss the natural history of the patient's disease and prognosis with the family and palliative care team to anticipate and manage symptoms and problems commonly associated with the diagnosis and treatment of cancer.

Palliative care is intensified late in the course of disease to help patients and families understand the disease and begin to make end-of-life plans. Sometimes patients and families do not accept the prognosis or do not begin to make preparations.^{319,320} These things may be a sign that patients do not fully understand the disease and may lead to the desire by patients and families for aggressive treatments that may be both futile and toxic.³²⁰ Palliative care supports education so that patients can better understand the disease.

Oncologists must ensure that advance care plans are in place as early as possible in the disease trajectory. This focus on the patients' wishes assures patients that they will be provided with no more and no less aggressive care than they desire and also relieves them of concerns about burdening family members with difficult end-of-life decisions. The combined efforts of the oncology team and the hospice/palliative care team can improve the overall outcome for patients and their families.



Psychosocial Support for Palliative Care Providers

After the loss of a patient, psychosocial support should be provided for the staff. A bereavement or memorial ritual for medical staff (eg, brief reading, moment of quiet) can be considered. Funeral attendance by health care professionals can be considered for individual patients. Health care professionals should also review medical issues related to patient death, explore concerns and questions about quality of patient care, and review emotional responses of family and staff to the patient's death.

Oncology and palliative care teams commonly encounter patient loss and deal with grief, and over time the resultant emotional distress can lead to provider burnout, compassion fatigue, and/or moral distress.³²¹⁻³²⁴ These syndromes can manifest as symptoms of depression, anxiety, fatigue, and low mental quality of life.³²⁵ Such staff should be identified and assisted. Unfortunately, although considerable research has been dedicated to evaluating patterns and interventions to mediate patient, family, and caregiver distress and grief, much less attention has been devoted to these same issues among health care providers and teams. For a summary of the literature on provider compassion fatigue in oncology, see reviews by Najjar and colleagues (2009),³²¹ Shanafelt and Dyrbye (2012),³²⁵ and Sherman and colleagues (2006).³²⁶

Although limited in quantity, most studies on compassion fatigue are derived from the oncology nursing literature. A large survey of hospice and palliative care providers (ie, clinical, administrative, allied health workers) revealed a strong correlation between burnout and compassion fatigue, and revealed the need for enhanced support of individuals in this field.³²⁷ Additionally, a cross-sectional survey of nurses, medical assistants, and radiology technicians at a

comprehensive cancer center revealed concerning levels of burnout and compassion fatigue in both inpatient and outpatient care settings.³²⁸

Qualitative research on compassion fatigue interventions reveals that oncology clinicians rated the following resources as helpful: educational interventions, support programs or resources in the workplace, retreats, and self-care measures.^{321,329} Unfortunately, despite the reported desire for such interventions, access can be limited. In a nationwide survey of oncology nurses, only 60% of survey respondents reported access to an employee assistance program, 45% reported no offerings of education addressing workplace coping, and 82% of respondents reported no off-site programs such as retreats.³²⁹ Generally, evidence-based interventions for compassion fatigue and burnout in physicians are lacking. When asked to provide useful preventative measures and coping strategies, palliative care specialists recommended emphasizing the rewarding aspects of their work and strategies for “enhanced meaning-making.”³³⁰ Experts in the field have also highlighted the importance of self-awareness and self-care measures for oncologists and palliative care specialists to decrease levels of compassion fatigue.³³¹ To this end, self-care was established as a core competency area for fellows in hospice and palliative medicine.³³¹ Examples and evidence for additional preventative strategies and solutions for oncologist burnout are reviewed by Shanafelt and Dyrbye.³²⁵

Hope

These guidelines are intended to help oncology teams provide the best care possible for patients with incurable cancer. Palliative care can help patients and families meet short-term goals, such as important life-cycle events, and achieve realistic expectations. In this sense, the care outlined in these guidelines provides a different kind of hope than that



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2014

Palliative Care

[NCCN Guidelines Index](#)
[Palliative Care Table of Contents](#)
[Discussion](#)

for cure of the disease itself. Palliative care provides hope for dignity, comfort, and closure and for growth at the end of life.



Table 1: Palliative Care Internet Resources for Clinicians^a

Palliative Care Clinical Competencies

www.epec.net

Education in Palliative and End-of-life Care (EPEC): Comprehensive curriculum covering fundamentals of palliative medicine; teaching guides

<http://www.eperc.mcw.edu/EPERC.htm>

End of Life/Palliative Education Resource Center (EPERC): Medical educator resources for peer-reviewed palliative care teaching materials

www.StopPain.org

Department of Pain Medicine and Palliative Care at Beth Israel Medical Center: Online education for physicians, nurses, and pharmacists

Clinical, Educational, Professional, and Public Resources

www.palliativedrugs.com

Palliativedrugs.com: Extensive information on pharmacologic symptom management

www.aahpm.org

American Academy of Hospice and Palliative Medicine: Physician membership organization; board review courses; publications

<http://www.abim.org>

The American Board of Internal Medicine: Physician Board Certification

<http://www.nhpco.org/templates/1/homepage.cfm>

National Hospice and Palliative Care Organization: Nonprofit membership organization representing hospice and palliative care programs and professionals in the United States.

<http://www.hpna.org/>

Hospice and Palliative Nurses Association: Specialty nursing organization with evidence-based educational tools for the nursing team

www.hms.harvard.edu/cdi/pallcare

Center for Palliative Care at Harvard Medical School: Faculty development courses, other educational programs

<http://www.nationalconsensusproject.org/>

National Consensus Project for Quality Palliative Care: Clinical practice guidelines

www.americangeriatrics.org/

American Geriatrics Society: Clinical guidelines and continuing education

Palliative Care Program Development

www.capc.org

Center to Advance Palliative Care: Technical assistance for clinicians and hospitals seeking to establish or strengthen a palliative care program

www.capc.org/pclc

Palliative Care Leadership Centers: Eight exemplary palliative care programs providing site visits, hands-on training, and technical assistance to support new palliative care clinicians and programs nationwide

^a All websites accessed March 2014.

Adapted with permission from Meier DE et al. *Oncology* 2005;19. Available at <http://www.cancernetwork.com/display/article/10165/104428>.



References

1. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014. Available at: <http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf>. Accessed February 28, 2014.
2. Cancer survivors--United States, 2007. MMWR Morb Mortal Wkly Rep 2011;60:269-272. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21389929>.
3. Ferris FD, Bruera E, Cherny N, et al. Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. J Clin Oncol 2009;27:3052-3058. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19451437>.
4. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-241. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22700443>.
5. Becker G, Hatami I, Xander C, et al. Palliative cancer care: an epidemiologic study. J Clin Oncol 2011;29:646-650. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21263094>.
6. Seow H, Barbera L, Sutradhar R, et al. Trajectory of Performance Status and Symptom Scores for Patients With Cancer During the Last Six Months of Life. J Clin Oncol 2011. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21300920>.
7. Berger A, Portenoy R, Weissman D, eds. Practice and Principles of Supportive Oncology. Philadelphia: Lippincott-Raven; 1998.
8. Doyle D, Hanks G, MacDonald Ne, eds. Oxford Textbook of Palliative Medicine. Oxford: Oxford University; 1998.
9. Emanuel L, von Gunten C, FD F, eds. The Education for Physicians on End-of-Life Care (EPEC) Curriculum. Princeton: The Robert Wood Johnson Foundation; 1999.
10. Peppercorn JM, Smith TJ, Helft PR, et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011;29:755-760. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21263086>.
11. Smith TJ, Schnipper LJ. The American Society of Clinical Oncology program to improve end-of-life care. J Palliat Med 1998;1:221-230. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15859832>.
12. Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1990;804:1-75. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1702248>.
13. Levy MH. Living with cancer: hospice/palliative care. J Natl Cancer Inst 1993;85:1283-1287. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7688053>.
14. Levy MH. Supportive oncology: forward. Semin Oncol 1994;21:699-700. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7527594>.
15. MacDonald N. Palliative care--the fourth phase of cancer prevention. Cancer Detect Prev 1991;15:253-255. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1711926>.
16. Elsayem A, Swint K, Fisch MJ, et al. Palliative Care Inpatient Service in a Comprehensive Cancer Center: Clinical and Financial Outcomes. J Clin Oncol 2004;22:2008-2014. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15143094>.
17. Levy M. NCCN Task Force reports: Supportive and Palliative Care. Oncology 1999;13:517-522.
18. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 1995;274:1591-1598. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7474243>.



19. Malin JL. Bridging the divide: integrating cancer-directed therapy and palliative care. *J Clin Oncol* 2004;22:3438-3440. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15277538>.
20. Meyers FJ, Linder J. Simultaneous care: disease treatment and palliative care throughout illness. *J Clin Oncol* 2003;21:1412-1415. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12663735>.
21. Greer JA, Jackson VA, Meier DE, Temel JS. Early integration of palliative care services with standard oncology care for patients with advanced cancer. *CA Cancer J Clin* 2013;63:349-363. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23856954>.
22. Davis MP, Bruera E, Morganstern D. Early integration of palliative and supportive care in the cancer continuum: challenges and opportunities. *Am Soc Clin Oncol Educ Book* 2013;33:144-150. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23714482>.
23. Weissman DE. Decision making at a time of crisis near the end of life. *JAMA* 2004;292:1738-1743. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15479939>.
24. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010;363:733-742. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20818875>.
25. Greer JA, Pirl WF, Jackson VA, et al. Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Non-Small-Cell Lung Cancer. *J Clin Oncol* 2012;30:394-400. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22203758>.
26. Temel JS, Greer JA, Admane S, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. *J Clin Oncol* 2011;29:2319-2326. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21555700>.
27. McNamara BA, Rosenwax LK, Murray K, Currow DC. Early admission to community-based palliative care reduces use of emergency departments in the ninety days before death. *J Palliat Med* 2013;16:774-779. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23676094>.
28. Cruz VM, Camaliente L, Caruso P. Factors Associated With Futile End-Of-Life Intensive Care in a Cancer Hospital. *Am J Hosp Palliat Care* 2014. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24399608>
29. Jang RW, Krzyzanowska MK, Zimmermann C, et al. Intensity of Palliative Care and its Impact on the Aggressiveness of End-of-Life Care in Patients with Advanced Pancreatic Cancer [Abstract]. *J Clin Oncol* 2013;31(Suppl):Suppl; Abstract 9518. Available at: <http://meetinglibrary.asco.org/content/111841-132>.
30. Zimmermann C, Swami N, Krzyzanowska M, et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. *Lancet* 2014. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24559581>.
31. Gomes B, Calanzani N, Curiale V, et al. Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers. *Cochrane Database Syst Rev* 2013;6:CD007760. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23744578>.
32. Kamal AH, Bull J, Stinson CS, et al. Conformance with supportive care quality measures is associated with better quality of life in patients with cancer receiving palliative care. *J Oncol Pract* 2013;9:e73-76. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23942504>.
33. Morita T, Miyashita M, Yamagishi A, et al. Effects of a programme of interventions on regional comprehensive palliative care for patients with cancer: a mixed-methods study. *Lancet Oncol* 2013;14:638-646. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23664708>.



34. Rocque GB, Cleary JF. Palliative care reduces morbidity and mortality in cancer. *Nat Rev Clin Oncol* 2013;10:80-89. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23247373>.

35. Khan SA, Gomes B, Higginson IJ. End-of-life care-what do cancer patients want? *Nat Rev Clin Oncol* 2014;11:100-108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24281062>.

36. Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care into Standard Oncology Care. *J Clin Oncol* 2012;30:880-887. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22312101>.

37. Vergo MT, Cullinan AM. Joining together to improve outcomes: integrating specialty palliative care into the care of patients with cancer. *J Natl Compr Canc Netw* 2013;11 Suppl 4:S38-46. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24158970>.

38. Abrahm JL. Integrating palliative care into comprehensive cancer care. *J Natl Compr Canc Netw* 2012;10:1192-1198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23054873>.

39. Alesi ER, Fletcher D, Muir C, et al. Palliative care and oncology partnerships in real practice. *Oncology (Williston Park)* 2011;25:1287-1290, 1292-1283. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22272501>.

40. Bruera E, Yennurajalingam S. Palliative care in advanced cancer patients: how and when? *Oncologist* 2012;17:267-273. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22252934>.

41. Dennis K, Librach SL, Chow E. Palliative care and oncology: integration leads to better care. *Oncology (Williston Park)* 2011;25:1271-1275. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22272495>.

42. Marchetti P, Voltz R, Rubio C, et al. Provision of palliative care and pain management services for oncology patients. *J Natl Compr Canc*

Netw 2013;11 Suppl 1:S17-27. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23520182>.

43. Quill TE, Abernethy AP. Generalist plus specialist palliative care--creating a more sustainable model. *N Engl J Med* 2013;368:1173-1175. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23465068>.

44. Ramchandran K, Von Roenn JH. Palliative care always. *Oncology (Williston Park)* 2013;27:13-16, 27-30, 32-14 passim. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23461040>.

45. Von Roenn JH, Voltz R, Serrie A. Barriers and approaches to the successful integration of palliative care and oncology practice. *J Natl Compr Canc Netw* 2013;11 Suppl 1:S11-16. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23520181>.

46. Rangachari D, Smith TJ. Integrating palliative care in oncology: the oncologist as a primary palliative care provider. *Cancer J* 2013;19:373-378. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24051609>.

47. Fann JR, Ell K, Sharpe M. Integrating psychosocial care into cancer services. *J Clin Oncol* 2012;30:1178-1186. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22412139>.

48. Bergman J, Saigal CS, Lorenz KA, et al. Hospice use and high-intensity care in men dying of prostate cancer. *Arch Intern Med* 2011;171:204-210. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20937914>.

49. Breitkopf CR, Stephens EK, Jatoi A. Hospice in End-of-Life Patients With Cancer: Does It Lead to Changes in Nonhospice Health Care Utilization After Stopping Cancer Treatment? *Am J Hosp Palliat Care* 2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23666617>.

50. Kelley AS, Deb P, Du Q, et al. Hospice enrollment saves money for Medicare and improves care quality across a number of different lengths-of-stay. *Health Aff (Millwood)* 2013;32:552-561. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23459735>.



51. Han B, Remsburg RE, McAuley WJ, et al. National trends in adult hospice use: 1991-1992 to 1999-2000. *Health Aff (Millwood)* 2006;25:792-799. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16684745>.
52. NHPCO Facts and Figures: Hospice Care in America. Alexandria, VA: National Hospice and Palliative Care Organization; 2013. Available at: http://www.nhpco.org/sites/default/files/public/Statistics_Research/2013_Facts_Figures.pdf.
53. NHPCO Facts and Figures: Hospice Care in America. National Hospice and Palliative Care Organization; 2012. Available at: http://www.nhpco.org/sites/default/files/public/Statistics_Research/2012_Facts_Figures.pdf. Accessed March 20, 2013.
54. Mack JW, Chen K, Boscoe FP, et al. Underuse of hospice care by Medicaid-insured patients with stage IV lung cancer in New York and California. *J Clin Oncol* 2013;31:2569-2579. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23733768>.
55. Morden NE, Chang CH, Jacobson JO, et al. End-of-life care for Medicare beneficiaries with cancer is highly intensive overall and varies widely. *Health Aff (Millwood)* 2012;31:786-796. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22492896>.
56. Earle CC, Neville BA, Landrum MB, et al. Trends in the Aggressiveness of Cancer Care Near the End of Life. *J Clin Oncol* 2004;22:315-321. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14722041>.
57. Earle CC, Landrum MB, Souza JM, et al. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? *J Clin Oncol* 2008;26:3860-3866. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18688053>.
58. Foley K, Gelband H, eds. Improving palliative care for cancer. Washington, DC: National Academy Press; 2001.
59. Goodman D, Morden NE, Chang CH, et al. Trends in Cancer Care Near the End of Life. A Dartmouth Atlas of Health Care Brief: The Dartmouth Institute for Health Policy and Clinical Practice; 2013. Available at: http://www.dartmouthatlas.org/downloads/reports/Cancer_brief_090413.pdf.
60. Lorenz KA, Lynn J, Dy SM, et al. Evidence for improving palliative care at the end of life: a systematic review. *Ann Intern Med* 2008;148:147-159. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18195339>.
61. National Consensus Project for Quality Palliative Care. Clinical Practice Guidelines for Quality Palliative Care, Third Edition. 2013. Available at: <http://www.nationalconsensusproject.org>.
62. National Quality Forum: A National Framework and Preferred Practices for Palliative and Hospice Care Quality. 2006. Available at: <http://www.qualityforum.org/Home.aspx>.
63. Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. *Ann Intern Med* 2008;148:141-146. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18195338>.
64. Cancer Program Standards 2012: Ensuring Patient-Centered Care. American College of Surgeons Commission on Cancer; 2012. Available at: <http://www.facs.org/cancer/coc/programstandards2012.html>. Accessed March 20, 2013.
65. National Cancer Control Programmes: Policies and Managerial Guidelines (ed 2). Geneva: World Health Organization; 2002.
66. Levy MH. Supportive oncology-palliative care: what's in a name? *Semin Oncol* 2005;32:131-133. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15815956>.



67. Von Roenn JH. Optimal cancer care: Concurrent oncology and palliative care. *J Natl Compr Canc Netw* 2013;11 Suppl 1:S1-2. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23520180>.

68. Hui D, Mori M, Parsons HA, et al. The lack of standard definitions in the supportive and palliative oncology literature. *J Pain Symptom Manage* 2012;43:582-592. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22104619>.

69. Hui D, De La Cruz M, Mori M, et al. Concepts and definitions for "supportive care," "best supportive care," "palliative care," and "hospice care" in the published literature, dictionaries, and textbooks. *Support Care Cancer* 2013;21:659-685. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22936493>.

70. Rittenberg CN, Johnson JL, Kuncio GM. An oral history of MASCC, its origin and development from MASCC's beginnings to 2009. *Support Care Cancer* 2010;18:775-784. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20221642>.

71. Maciasz RM, Arnold RM, Chu E, et al. Does it matter what you call it? A randomized trial of language used to describe palliative care services. *Support Care Cancer* 2013;21:3411-3419. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23942596>.

72. Fadul N, Elsayem A, Palmer JL, et al. Supportive versus palliative care: what's in a name?: a survey of medical oncologists and midlevel providers at a comprehensive cancer center. *Cancer* 2009;115:2013-2021. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19235253>.

73. Dalal S, Palla S, Hui D, et al. Association between a name change from palliative to supportive care and the timing of patient referrals at a comprehensive cancer center. *Oncologist* 2011;16:105-111. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21212438>.

74. Chochinov HM. Dying, dignity, and new horizons in palliative end-of-life care. *CA Cancer J Clin* 2006;56:84-103; quiz 104-105. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16514136>.

75. Kim A, Fall P, Wang D. Palliative care: optimizing quality of life. *J Am Osteopath Assoc* 2005;105:S9-14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16368908>.

76. Hui D, Kim SH, Kwon JH, et al. Access to palliative care among patients treated at a comprehensive cancer center. *Oncologist* 2012;17:1574-1580. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23220843>.

77. Wentlandt K, Krzyzanowska MK, Swami N, et al. Referral practices of oncologists to specialized palliative care. *J Clin Oncol* 2012;30:4380-4386. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23109708>.

78. Reville B, Reifsnnyder J, McGuire DB, et al. Education and referral criteria: impact on oncology referrals to palliative care. *J Palliat Med* 2013;16:786-789. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23510168>.

79. Pelayo-Alvarez M, Perez-Hoyos S, Agra-Varela Y. Clinical effectiveness of online training in palliative care of primary care physicians. *J Palliat Med* 2013;16:1188-1196. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23987657>.

80. Mougalian SS, Lessen DS, Levine RL, et al. Palliative care training and associations with burnout in oncology fellows. *J Support Oncol* 2013;11:95-102. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23967496>.

81. Buss MK, Lessen DS, Sullivan AM, et al. Hematology/oncology fellows' training in palliative care: Results of a national survey. *Cancer* 2011;117:4304-4311. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21365618>.

82. de Haes H, Teunissen S. Communication in palliative care: a review of recent literature. *Curr Opin Oncol* 2005;17:345-350. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15933465>.

83. Sinclair CT. Communicating a prognosis in advanced cancer. *J Support Oncol* 2006;4:201-204. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16669464>.

84. van Vliet LM, van der Wall E, Plum NM, Bensing JM. Explicit prognostic information and reassurance about nonabandonment when entering palliative breast cancer care: findings from a scripted video-vignette study. *J Clin Oncol* 2013;31:3242-3249. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23940230>.

85. Furber L, Cox K, Murphy R, Steward W. Investigating communication in cancer consultations: what can be learned from doctor and patient accounts of their experience? *Eur J Cancer Care (Engl)* 2013;22:653-662. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23701317>.

86. Ciechanowski PS, Katon WJ, Russo JE, Walker EA. The patient-provider relationship: attachment theory and adherence to treatment in diabetes. *Am J Psychiatry* 2001;158:29-35. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11136630>.

87. Stewart MA. Effective physician-patient communication and health outcomes: a review. *CMAJ* 1995;152:1423-1433. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7728691>.

88. Grenklo TB, Kreicbergs UC, Valdimarsdottir UA, et al. Communication and trust in the care provided to a dying parent: a nationwide study of cancer-bereaved youths. *J Clin Oncol* 2013;31:2886-2894. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23857973>.

89. Mack JW, Smith TJ. Reasons why physicians do not have discussions about poor prognosis, why it matters, and what can be improved. *J Clin Oncol* 2012;30:2715-2717. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22753911>.

90. Otani H, Morita T, Esaki T, et al. Burden on oncologists when communicating the discontinuation of anticancer treatment. *Jpn J Clin*

Oncol 2011;41:999-1006. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21764830>.

91. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. *N Engl J Med* 2012;367:1616-1625. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23094723>.

92. Smith TJ, Longo DL. Talking with patients about dying. *N Engl J Med* 2012;367:1651-1652. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23094729>.

93. Chen AB, Cronin A, Weeks JC, et al. Expectations about the effectiveness of radiation therapy among patients with incurable lung cancer. *J Clin Oncol* 2013;31:2730-2735. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23775958>.

94. Barth J, Lannen P. Efficacy of communication skills training courses in oncology: a systematic review and meta-analysis. *Ann Oncol* 2011;22:1030-1040. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20974653>.

95. Kissane DW, Bylund CL, Banerjee SC, et al. Communication skills training for oncology professionals. *J Clin Oncol* 2012;30:1242-1247. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22412145>.

96. Moore PM, Rivera Mercado S, Grez Artigues M, Lawrie TA. Communication skills training for healthcare professionals working with people who have cancer. *Cochrane Database Syst Rev* 2013;3:CD003751. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23543521>.

97. Rao JK, Anderson LA, Inui TS, Frankel RM. Communication interventions make a difference in conversations between physicians and patients: a systematic review of the evidence. *Med Care* 2007;45:340-349. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17496718>.

98. Krasner MS, Epstein RM, Beckman H, et al. Association of an educational program in mindful communication with burnout, empathy, and attitudes among primary care physicians. *JAMA* 2009;302:1284-1293. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19773563>.
99. Goelz T, Wuensch A, Stubenrauch S, et al. Specific training program improves oncologists' palliative care communication skills in a randomized controlled trial. *J Clin Oncol* 2011;29:3402-3407. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21825268>.
100. Cleeland CS, Zhao F, Chang VT, et al. The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. *Cancer* 2013;119:4333-4340. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24114037>.
101. Diver E, O'Connor O, Garrett L, et al. Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. *Gynecol Oncol* 2013;129:332-335. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23402902>.
102. Richards DM, Tanikella R, Arora G, et al. Percutaneous endoscopic gastrostomy in cancer patients: predictors of 30-day complications, 30-day mortality, and overall mortality. *Dig Dis Sci* 2013;58:768-776. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23007733>.
103. Salpeter SR, Malter DS, Luo EJ, et al. Systematic review of cancer presentations with a median survival of six months or less. *J Palliat Med* 2012;15:175-185. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22023378>.
104. El-Jawahri A, Traeger L, Park ER, et al. Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer. *Cancer* 2014;120:278-285. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24122784>.
105. Gwilliam B, Keeley V, Todd C, et al. Prognosticating in patients with advanced cancer—observational study comparing the accuracy of clinicians' and patients' estimates of survival. *Ann Oncol* 2013;24:482-488. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23028038>.
106. Hagerty RG, Butow PN, Ellis PA, et al. Cancer patient preferences for communication of prognosis in the metastatic setting. *J Clin Oncol* 2004;22:1721-1730. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15117995>.
107. Hagerty RG, Butow PN, Ellis PM, et al. Communicating With Realism and Hope: Incurable Cancer Patients' Views on the Disclosure of Prognosis. *J Clin Oncol* 2005;23:1278-1288. Available at: <http://www.jco.org/cgi/content/abstract/23/6/1278>.
108. Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. *JAMA* 1998;279:1709-1714. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9624023>.
109. Lo B, Ruston D, Kates LW, et al. Discussing religious and spiritual issues at the end of life: a practical guide for physicians. *JAMA* 2002;287:749-754. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11851542>.
110. Communicating with Patients on Health Care Evidence. Institute of Medicine; 2012. Available at: <http://www.iom.edu/Global/Perspectives/2012/Evidence.aspx>. Accessed May 17, 2013.
111. Novelli WD, Halvorson GC, Santa J. Recognizing an Opinion: Findings From the IOM Evidence Communication Innovation Collaborative *JAMA* 2012;308:1531-1532. Available at: <http://jama.jamanetwork.com/article.aspx?articleid=1363268>.
112. Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. *Am Fam Physician* 2006;73:485-492. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16477897>.

113. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. *Eur J Nucl Med Mol Imaging* 2004;31 Suppl 1:S149-161. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15107948>.

114. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. *CA Cancer J Clin* 2005;55:300-318; quiz 323-305. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16166075>.

115. Prommer E. Guidelines for the Use of Palliative Chemotherapy. *AAHPM Bulletin* 2004;5:2-13. Available at: <http://www.aahpm.org/pdf/04spring.pdf>.

116. Ajani JA. Evolving chemotherapy for advanced gastric cancer. *Oncologist* 2005;10 Suppl 3:49-58. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16368871>.

117. Brown J, Thorpe H, Napp V, et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. *J Clin Oncol* 2005;23:7417-7427. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16157935>.

118. Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. *Chest* 2005;128:3975-3984. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16354869>.

119. Chen AB, Cronin A, Weeks JC, et al. Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. *J Clin Oncol* 2013;31:558-564. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23295799>.

120. Zafar SY, Malin JL, Grambow SC, et al. Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study. *Cancer* 2013;119:854-862. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22972673>.

121. Higginson IJ, Finlay IG, Goodwin DM, et al. Is there evidence that palliative care teams alter end-of-life experiences of patients and their caregivers? *J Pain Symptom Manage* 2003;25:150-168. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12590031>.

122. Kinzbrunner BM. Hospice: what to do when anti-cancer therapy is no longer appropriate, effective, or desired. *Semin Oncol* 1994;21:792-798. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7527597>.

123. Trajkovic-Vidakovic M, de Graeff A, Voest EE, Teunissen SC. Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients. *Crit Rev Oncol Hematol* 2012;84:130-148. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22465016>.

124. Yennurajalingam S, Kwon JH, Urbauer DL, et al. Consistency of symptom clusters among advanced cancer patients seen at an outpatient supportive care clinic in a tertiary cancer center. *Palliat Support Care* 2013;11:473-480. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23388652>.

125. Van Lancker A, Velghe A, Van Hecke A, et al. Prevalence of symptoms in older cancer patients receiving palliative care: a systematic review and meta-analysis. *J Pain Symptom Manage* 2014;47:90-104. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23764109>.

126. Ferrell B, Levy MH, Paice J. Managing pain from advanced cancer in the palliative care setting. *Clin J Oncol Nurs* 2008;12:575-581. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18676325>.

127. Temel JS, Pirl WF, Lynch TJ. Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer. *Clin Lung Cancer* 2006;7:241-249. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16512977>.

128. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. *Am J Respir Crit*



Care Med 1999;159:321-340. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/9872857>.

129. DeCamp MM, Jr., Mentzer SJ, Swanson SJ, Sugarbaker DJ. Malignant effusive disease of the pleura and pericardium. Chest 1997;112:291S-295S. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/9337306>.

130. Dy SM, Lorenz KA, Naeim A, et al. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 2008;26:3886-3895. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/18688057>.

131. Swanson N, Mirza I, Wijesinghe N, Devlin G. Primary percutaneous balloon pericardiectomy for malignant pericardial effusion. Catheter Cardiovasc Interv 2008;71:504-507. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/18307242>.

132. Xue D, Abernethy AP. Management of dyspnea in advanced lung cancer: recent data and emerging concepts. Curr Opin Support Palliat Care 2010;4:85-91. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20440205>.

133. Dy SM, Apostol CC. Evidence-based approaches to other symptoms in advanced cancer. Cancer J 2010;16:507-513. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20890148>.

134. Ben-Aharon I, Gafter-Gvili A, Paul M, et al. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008;26:2396-2404. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/18467732>.

135. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis. Acta Oncol 2012;51:996-1008. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/22934558>.

136. Clemens KE, Quednau I, Klaschik E. Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med 2008;11:204-216. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/18333735>.

137. Gomutbutra P, O'Riordan DL, Pantilat SZ. Management of Moderate-to-Severe Dyspnea in Hospitalized Patients Receiving Palliative Care. J Pain Symptom Manage 2012. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/22940561>.

138. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57:939-944. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/12403875>.

139. Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010:CD007354. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20091630>.

140. Coyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 2002;23:157-160. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11844637>.

141. Smith TJ, Coyne P, French W, et al. Failure to accrue to a study of nebulized fentanyl for dyspnea: lessons learned. J Palliat Med 2009;12:771-772. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/19719370>.

142. Simon ST, Koskeroglu P, Gaertner J, Voltz R. Fentanyl for the relief of refractory breathlessness: a systematic review. J Pain Symptom Manage 2013;46:874-886. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/23742735>.

143. Hui D, Xu A, Frisbee-Hume S, et al. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in

cancer patients: a preliminary double-blind, randomized, controlled trial. *J Pain Symptom Manage* 2014;47:209-217. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23830530>.

144. Jensen D, Alsu hail A, Viola R, et al. Inhaled Fentanyl Citrate Improves Exercise Endurance During High-Intensity Constant Work Rate Cycle Exercise in Chronic Obstructive Pulmonary Disease. *J Pain Symptom Manage* 2011. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22168961>.

145. Kawabata M, Kaneishi K. Continuous subcutaneous infusion of compound oxycodone for the relief of dyspnea in patients with terminally ill cancer: a retrospective study. *Am J Hosp Palliat Care* 2013;30:305-311. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22669937>.

146. Back IN, Jenkins K, Blower A, Beckhelling J. A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle. *Palliat Med* 2001;15:329-336. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12054150>.

147. Davis MP, Furste A. Glycopyrrolate: a useful drug in the palliation of mechanical bowel obstruction. *J Pain Symptom Manage* 1999;18:153-154. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10517034>.

148. Hughes A, Wilcock A, Corcoran R, et al. Audit of three antimuscarinic drugs for managing retained secretions. *Palliat Med* 2000;14:221-222. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10858832>.

149. Wildiers H, Menten J. Death rattle: prevalence, prevention and treatment. *J Pain Symptom Manage* 2002;23:310-317. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11997200>.

150. Wildiers H, Dhaenekint C, Demeulenaere P, et al. Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. *J Pain Symptom Manage*

2009;38:124-133. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19361952>.

151. Mirakhor RK, Dundee JW. Glycopyrrolate: pharmacology and clinical use. *Anaesthesia* 1983;38:1195-1204. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6660460>.

152. Grum DF, Osborne LR. Central anticholinergic syndrome following glycopyrrolate. *Anesthesiology* 1991;74:191-193. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1986648>.

153. Wingard DW. Glycopyrrolate and the central anticholinergic syndrome. *Anesthesiology* 1991;75:1125-1126. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1741510>.

154. #109 Death Rattle and Oral Secretions, 2nd ed. End of Life / Palliative Education Resource Center (EPEC); Available at: http://www.eperc.mcw.edu/EPEC/FastFactsIndex/ff_109.htm. Accessed May 20, 2013.

155. Galbraith S, Fagan P, Perkins P, et al. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. *J Pain Symptom Manage* 2010;39:831-838. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20471544>.

156. Nava S, Ferrer M, Esquinas A, et al. Palliative use of non-invasive ventilation in end-of-life patients with solid tumours: a randomised feasibility trial. *Lancet Oncol* 2013;14:219-227. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23406914>.

157. Hui D, Morgado M, Chisholm G, et al. High-flow oxygen and bilevel positive airway pressure for persistent dyspnea in patients with advanced cancer: a phase II randomized trial. *J Pain Symptom Manage* 2013;46:463-473. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23739633>.

158. Kumar NB, Kazi A, Smith T, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to



treatment. *Curr Treat Options Oncol* 2010;11:107-117. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21128029>.

159. Laviano A, Meguid MM, Inui A, et al. Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself. *Nat Clin Pract Oncol* 2005;2:158-165. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16264909>.

160. Oberholzer R, Hopkinson JB, Baumann K, et al. Psychosocial Effects of Cancer Cachexia: A Systematic Literature Search and Qualitative Analysis. *J Pain Symptom Manage* 2012. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23159682>.

161. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. *J Clin Oncol* 2013;31:1539-1547. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23530101>.

162. Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. *J Pain Symptom Manage* 2004;27:360-369. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15050664>.

163. Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. *Cochrane Database Syst Rev* 2013;3:CD004310. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23543530>.

164. Yavuzsen T, Davis MP, Walsh D, et al. Systematic review of the treatment of cancer-associated anorexia and weight loss. *J Clin Oncol* 2005;23:8500-8511. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16293879>.

165. Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. *Oncologist* 2010;15:200-211. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20156909>.

166. Maccio A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. *Gynecol Oncol* 2012;124:417-425. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22198049>.

167. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. *Support Care Cancer* 2003;11:137-143. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12618922>.

168. Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. *J Clin Oncol* 2006;24:3394-3400. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16849753>.

169. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. *J Clin Oncol* 2002;20:567-573. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11786587>.

170. Isenring EA, Capra S, Bauer JD. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. *Br J Cancer* 2004;91:447-452. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15226773>.

171. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. *J Clin Oncol* 2005;23:1431-1438. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15684319>.

172. Trentham K. Palliative Care. In: Marian M, Roberts S, eds. Clinical Nutrition for Oncology Patients. Sudbury, MA: Jones and Bartlett Publishers LLC; 2010.

173. Baldwin C, Spiro A, McGough C, et al. Simple nutritional intervention in patients with advanced cancers of the gastrointestinal tract, non-small cell lung cancers or mesothelioma and weight loss receiving chemotherapy: a randomised controlled trial. J Hum Nutr Diet 2011;24:431-440. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21733143>.

174. Baldwin C, Spiro A, Ahern R, Emery PW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2012;104:371-385. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22345712>.

175. August DA, Huhmann MB. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 2009;33:472-500. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19713551>.

176. McCann RM, Hall WJ, Groth-Juncker A. Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994;272:1263-1266. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7523740>.

177. Weiner RS, Kramer BS, Clamon GH, et al. Effects of intravenous hyperalimentation during treatment in patients with small-cell lung cancer. J Clin Oncol 1985;3:949-957. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2991475>.

178. Winter SM. Terminal nutrition: framing the debate for the withdrawal of nutritional support in terminally ill patients. Am J Med 2000;109:723-726. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11137488>.

179. Bruera E, Hui D, Dalal S, et al. Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled

randomized trial. J Clin Oncol 2013;31:111-118. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23169523>.

180. Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 2006;4:3-8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16499138>.

181. Shoemaker LK, Estfan B, Induru R, Walsh TD. Symptom management: an important part of cancer care. Cleve Clin J Med 2011;78:25-34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21199904>.

182. Holt DW, Volans GN. Gastrointestinal symptoms of digoxin toxicity. Br Med J 1977;2:704. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/268993>.

183. Hwang WJ, Tsai JJ. Acute phenytoin intoxication: causes, symptoms, misdiagnoses, and outcomes. Kaohsiung J Med Sci 2004;20:580-585. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15696787>.

184. Hardy JR, O'Shea A, White C, et al. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manage 2010;40:111-116. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20619214>.

185. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905-909. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7024807>.

186. Buzdar AU, Esparza L, Natale R, et al. Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study. Am J Clin Oncol 1994;17:417-421. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8092114>.



187. Tan L, Liu J, Liu X, et al. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. *J Exp Clin Cancer Res* 2009;28:131. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19775450>.

188. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. *J Support Oncol* 2011;9:188-195. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22024310>.

189. Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. *J Clin Oncol* 1989;7:1137-1141. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2526864>.

190. Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine₃ (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. *N Engl J Med* 1990;322:816-821. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2137902>.

191. Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. *Cancer* 1987;60:2816-2822. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3315176>.

192. Aapro MS, Plezia PM, Alberts DS, et al. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. *J Clin Oncol* 1984;2:466-471. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6539363>.

193. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. *Support Care Cancer*

2005;13:529-534. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15700131>.

194. Herman TS, Einhorn LH, Jones SE, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. *N Engl J Med* 1979;300:1295-1297. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/375088>.

195. Morita T, Takigawa C, Onishi H, et al. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. *J Pain Symptom Manage* 2005;30:96-103. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16043013>.

196. Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. *J Support Oncol* 2007;5:1-9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17566383>.

197. Mamtani R, Cimino A. A primer of complementary and alternative medicine and its relevance in the treatment of mental health problems. *Psychiatr Q* 2002;73:367-381. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12418362>.

198. Mansky PJ, Wallerstedt DB. Complementary medicine in palliative care and cancer symptom management. *Cancer J* 2006;12:425-431. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17034678>.

199. Marchioro G, Azzarello G, Viviani F, et al. Hypnosis in the treatment of anticipatory nausea and vomiting in patients receiving cancer chemotherapy. *Oncology* 2000;59:100-104. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10971166>.

200. Davis MP, Hallerberg G. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. *J Pain Symptom Manage* 2010;39:756-767. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20413062>.



201. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. *J Pain Symptom Manage* 2007;34:547-565. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17900855>.

202. Mancini I, Bruera E. Constipation in advanced cancer patients. *Support Care Cancer* 1998;6:356-364. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9695203>.

203. Dhingra L, Shuk E, Grossman B, et al. A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. *Palliat Med* 2013;27:447-456. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22707180>.

204. American Pain Society. Principles of Analgesic use in the treatment of acute pain and cancer pain (ed 5th). Glenview, IL: American Pain Society; 2003.

205. Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. *J Palliat Med* 2008;11:575-581. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18454610>.

206. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. *J Pain Symptom Manage* 2008;35:458-468. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18440447>.

207. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. *N Engl J Med* 2008;358:2332-2343. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18509120>.

208. Francescutti V, Miller A, Satchidanand Y, et al. Management of bowel obstruction in patients with stage IV cancer: predictors of

outcome after surgery. *Ann Surg Oncol* 2013;20:707-714. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22990648>.

209. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. *Cochrane Database Syst Rev* 2000:CD001219. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10796761>.

210. Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. *J Pain Symptom Manage* 2012;44:604-607. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22771132>.

211. Porzio G, Aielli F, Verna L, et al. Can malignant bowel obstruction in advanced cancer patients be treated at home? *Support Care Cancer* 2011;19:431-433. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20872024>.

212. Mercadante S, Ferrera P, Villari P, Marrazzo A. Aggressive pharmacological treatment for reversing malignant bowel obstruction. *J Pain Symptom Manage* 2004;28:412-416. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15471659>.

213. Zelek L, Laval G, Asselain B. Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis. *J Clin Oncol* 2013;31:2519-2520. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23733778>.

214. Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. *J Pain Symptom Manage* 2007;33:217-223. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17280927>.

215. Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: twenty years after. *Crit Rev Oncol Hematol* 2012;83:388-392. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22277783>.



216. Currow DC, Clark K, Cartmill J, et al. A Multi-site, Fixed Dose, Parallel Arm, Double-blind, Placebo-controlled, Block Randomised Trial of the Addition of Infusional Octreotide or Placebo to Regular Ranitidine and Dexamethasone for the Evaluation of Vomiting Associated with Bowel Obstruction at the End of Life [Abstract]. 19th International Congress on Palliative Care. Montreal, Canada: Palliative Care McGill, McGill University; 2012:Abstract D08-B.

217. Baron TH. Interventional palliative strategies for malignant bowel obstruction. *Curr Oncol Rep* 2009;11:293-297. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19508834>.

218. Brooksbank MA, Game PA, Ashby MA. Palliative venting gastrostomy in malignant intestinal obstruction. *Palliat Med* 2002;16:520-526. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12465700>.

219. Palesh OG, Roscoe JA, Mustian KM, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. *J Clin Oncol* 2010;28:292-298. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19933917>.

220. Savard J, Ivers H, Villa J, et al. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. *J Clin Oncol* 2011;29:3580-3586. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21825267>.

221. Palesh O, Aldridge-Gerry A, Ulusakarya A, et al. Sleep disruption in breast cancer patients and survivors. *J Natl Compr Canc Netw* 2013;11:1523-1530. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24335687>.

222. Yennurajalingam S, Chisholm G, Palla SL, et al. Self-reported sleep disturbance in patients with advanced cancer: Frequency, intensity, and factors associated with response to outpatient supportive care consultation - A preliminary report. *Palliat Support Care* 2013;1-9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24182896>.

223. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991;14:540-545. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1798888>.

224. Payne RJ, Hier MP, Kost KM, et al. High prevalence of obstructive sleep apnea among patients with head and neck cancer. *J Otolaryngol* 2005;34:304-311. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16181591>.

225. Stern TP, Auckley D. Obstructive sleep apnea following treatment of head and neck cancer. *Ear Nose Throat J* 2007;86:101-103. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17385619>.

226. Antonescu-Turcu A, Parthasarathy S. CPAP and bi-level PAP therapy: new and established roles. *Respir Care* 2010;55:1216-1229. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20800002>.

227. Bassetti CL, Bornatico F, Fuhr P, et al. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. *Swiss Med Wkly* 2011;141:w13274. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22101745>.

228. Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. *Sleep Med* 2008;9:874-881. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18952497>.

229. Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. *Sleep* 1993;16:717-723. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8165385>.

230. Manconi M, Ferri R, Zucconi M, et al. Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. *Mov Disord* 2011;26:892-895. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21370262>.



231. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. *Neurology* 1999;52:938-943. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10102409>.

232. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). *Mov Disord* 2007;22:213-219. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17133582>.

233. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. *J Neurol Neurosurg Psychiatry* 2004;75:92-97. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14707315>.

234. Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. *Mov Disord* 2004;19:1414-1423. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15390050>.

235. Berger AM. Update on the state of the science: sleep-wake disturbances in adult patients with cancer. *Oncol Nurs Forum* 2009;36:E165-177. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19581220>.

236. Harsora P, Kessmann J. Nonpharmacologic management of chronic insomnia. *Am Fam Physician* 2009;79:125-130. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19178064>.

237. Jungquist CR, O'Brien C, Matteson-Rusby S, et al. The efficacy of cognitive-behavioral therapy for insomnia in patients with chronic pain. *Sleep Med* 2010;11:302-309. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20133188>.

238. Howell D, Oliver TK, Keller-Olaman S, et al. Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice. *Ann Oncol* 2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24287882>.

239. Garland SN, Carlson LE, Stephens AJ, et al. Mindfulness-based stress reduction compared with cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: a randomized, partially blinded, noninferiority trial. *J Clin Oncol* 2014;32:449-457. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24395850>.

240. Kim SW, Shin IS, Kim JM, et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. *Psychiatry Clin Neurosci* 2008;62:75-83. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18289144>.

241. Stewart SA. The effects of benzodiazepines on cognition. *J Clin Psychiatry* 2005;66 Suppl 2:9-13. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15762814>.

242. U.S. Food and Drug Administration. Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses. 2013. Available at: <http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm334738.htm>. Accessed March 3, 2014.

243. Bruera E, Fainsinger R, MacEachern T, Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. *Pain* 1992;50:75-77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1381072>.

244. 2011 Physicians' Desk Reference (ed 65). Montvale, NJ: PDR Network, LLC; 2010.

245. Escalante CP, Meyers C, Reuben JM, et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. *Cancer J*



2014;20:8-14. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24445757>.

246. Gong S, Sheng P, Jin H, et al. Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis. PLoS One 2014;9:e84391. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24416225>.

247. Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 2010;28:3673-3679. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20625123>.

248. Hovey E, de Souza P, Marx G, et al. Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Support Care Cancer 2014;22:1233-1242. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24337761>.

249. Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 2010;116:3513-3520. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20564068>.

250. Diagnostic and statistical manual of mental disorders (ed 4th). Washington, DC: American Psychiatric Association; 1994.

251. Bush SH, Kanji S, Pereira JL, et al. Treating an Established Episode of Delirium in Palliative Care: Expert Opinion and Review of the Current Evidence Base With Recommendations for Future Development. J Pain Symptom Manage 2014. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24480529>.

252. Irwin SA, Pirrello RD, Hirst JM, et al. Clarifying delirium management: practical, evidenced-based, expert recommendations for clinical practice. J Palliat Med 2013;16:423-435. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23480299>.

253. Hosie A, Davidson PM, Agar M, et al. Delirium prevalence, incidence, and implications for screening in specialist palliative care inpatient settings: a systematic review. Palliat Med 2013;27:486-498. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22988044>.

254. Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol 2012;30:1206-1214. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22412123>.

255. Devlin JW, Roberts RJ, Fong JJ, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010;38:419-427. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19915454>.

256. Grover S, Mattoo SK, Gupta N. Usefulness of Atypical Antipsychotics and Choline Esterase Inhibitors in Delirium: A Review. Pharmacopsychiatry 2011. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21394715>.

257. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306:1359-1369. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21954480>.

258. Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother 2006;40:1966-1973. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17047137>.

259. Jacobson SA. Delirium in the elderly. Psychiatr Clin North Am 1997;20:91-110. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9139298>.



260. Caraceni A, Nanni O, Maltoni M, et al. Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. *Cancer* 2000;89:1145-1149. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10964345>.

261. Kehl KA. Treatment of terminal restlessness: a review of the evidence. *J Pain Palliat Care Pharmacother* 2004;18:5-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15148006>.

262. Jacobsen PB, Wagner LI. A new quality standard: the integration of psychosocial care into routine cancer care. *J Clin Oncol* 2012;30:1154-1159. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22412134>.

263. Moreno PI, Stanton AL. Personal growth during the experience of advanced cancer: a systematic review. *Cancer J* 2013;19:421-430. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24051616>.

264. Northouse L, Williams AL, Given B, McCorkle R. Psychosocial care for family caregivers of patients with cancer. *J Clin Oncol* 2012;30:1227-1234. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22412124>.

265. Mack JW, Cronin A, Taback N, et al. End-of-Life Care Discussions Among Patients With Advanced Cancer: A Cohort Study. *Ann Intern Med* 2012;156:204-210. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22312140>.

266. Almack K, Cox K, Moghaddam N, et al. After you: conversations between patients and healthcare professionals in planning for end of life care. *BMC Palliat Care* 2012;11:15. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22985010>.

267. Kao CY, Wang HM, Tang SC, et al. Predictive factors for do-not-resuscitate designation among terminally ill cancer patients receiving care from a palliative care consultation service. *J Pain Symptom Manage* 2014;47:271-282. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23856097>.

268. Mack JW, Cronin A, Keating NL, et al. Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. *J Clin Oncol* 2012;30:4387-4395. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23150700>.

269. Doll KM, Stine JE, Van Le L, et al. Outpatient end of life discussions shorten hospital admissions in gynecologic oncology patients. *Gynecol Oncol* 2013;130:152-155. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23542684>

270. Zhang B, Nilsson ME, Prigerson HG. Factors important to patients' quality of life at the end of life. *Arch Intern Med* 2012;172:1133-1142. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22777380>.

271. Gomes B, Higginson IJ, Calanzani N, et al. Preferences for place of death if faced with advanced cancer: a population survey in England, Flanders, Germany, Italy, the Netherlands, Portugal and Spain. *Ann Oncol* 2012;23:2006-2015. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22345118>.

272. Jeurkar N, Farrington S, Craig TR, et al. Which hospice patients with cancer are able to die in the setting of their choice? Results of a retrospective cohort study. *J Clin Oncol* 2012;30:2783-2787. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22734023>.

273. Volandes AE, Paasche-Orlow MK, Mitchell SL, et al. Randomized controlled trial of a video decision support tool for cardiopulmonary resuscitation decision making in advanced cancer. *J Clin Oncol* 2013;31:380-386. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23233708>.

274. Stein RA, Sharpe L, Bell ML, et al. Randomized controlled trial of a structured intervention to facilitate end-of-life decision making in patients with advanced cancer. *J Clin Oncol* 2013;31:3403-3410. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23897967>.

275. Temel JS, Greer JA, Gallagher ER, et al. Electronic prompt to improve outpatient code status documentation for patients with

advanced lung cancer. *J Clin Oncol* 2013;31:710-715. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23284038>.

276. Elsayem A, Smith ML, Parmley L, et al. Impact of a palliative care service on in-hospital mortality in a comprehensive cancer center. *J Palliat Med* 2006;9:894-902. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16910804>.

277. Wright AA, Keating NL, Balboni TA, et al. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. *J Clin Oncol* 2010;28:4457-4464. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20837950>.

278. Poulouse JV, Do YK, Neo PS. Association between referral-to-death interval and location of death of patients referred to a hospital-based specialist palliative care service. *J Pain Symptom Manage* 2013;46:173-181. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23177723>

279. Khatcheressian J, Cassel JB, Lyckholm L, et al. Improving palliative and supportive care in cancer patients. *Oncology (Williston Park)* 2005;19:1365-1376; discussion 1377-1368, 1381-1362, 1384 passim. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16285228>.

280. Morrison RS, Meier DE. Clinical practice. Palliative care. *N Engl J Med* 2004;350:2582-2590. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15201415>.

281. Singer PA, Martin DK, Kelner M. Quality end-of-life care: patients' perspectives. *JAMA* 1999;281:163-168. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9917120>.

282. Byock I, ed *Dying Well: The Prospect for Growth at the End of Life*. New York: Riverhead Books; 1997.

283. Loggers ET, Starks H, Shannon-Dudley M, et al. Implementing a Death with Dignity program at a comprehensive cancer center. *N Engl J Med* 2013;368:1417-1424. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23574120>.

284. Vermont Department of Health, Agency of Human Services. Patient Choice and Control at End of Life. 2013. Available at: http://healthvermont.gov/family/end_of_life_care/patient_choice.aspx.

285. Oregon Public Health Division. Oregon's Death with Dignity Act-2012. 2012. Available at: <http://public.health.oregon.gov/ProviderPartnerResources/EvaluationResearch/DeathwithDignityAct/Documents/year15.pdf>

286. Washington State Department of Health. Washington State Department of Health 2012 Death with Dignity Act Report. 2012. Available at: <http://www.doh.wa.gov/portals/1/Documents/Pubs/422-109-DeathWithDignityAct2012.pdf>. Accessed March 5, 2014.

287. Braun TC, Hagen NA, Clark T. Development of a clinical practice guideline for palliative sedation. *J Palliat Med* 2003;6:345-350. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14509479>.

288. Cherny NI, Portenoy RK. Sedation in the management of refractory symptoms: guidelines for evaluation and treatment. *J Palliat Care* 1994;10:31-38. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8089815>.

289. Cowan JD, Palmer TW. Practical guide to palliative sedation. *Curr Oncol Rep* 2002;4:242-249. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11937015>.

290. Levy MH, Cohen SD. Sedation for the relief of refractory symptoms in the imminently dying: a fine intentional line. *Semin Oncol* 2005;32:237-246. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15815971>.

291. Sykes N, Thorns A. The use of opioids and sedatives at the end of life. *Lancet Oncol* 2003;4:312-318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12732169>.

292. Wein S. Sedation in the imminently dying patient. *Oncology (Williston Park)* 2000;14:585-592; discussion 592, 597-588, 601. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10826317>.

293. Maltoni M, Pittureri C, Scarpi E, et al. Palliative sedation therapy does not hasten death: results from a prospective multicenter study. *Ann Oncol* 2009;20:1163-1169. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19542532>.

294. Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival: a systematic review. *J Clin Oncol* 2012;30:1378-1383. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22412129>.

295. Cherny NI, Radbruch L. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. *Palliat Med* 2009;23:581-593. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19858355>.

296. Mercadante S, Porzio G, Valle A, et al. Palliative sedation in advanced cancer patients followed at home: a retrospective analysis. *J Pain Symptom Manage* 2012;43:1126-1130. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22651952>.

297. Mercadante S, Porzio G, Valle A, et al. Palliative Sedation in Patients With Advanced Cancer Followed at Home: A Prospective Study. *J Pain Symptom Manage* 2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24099896>.

298. Lindqvist O, Tishelman C, Hagelin CL, et al. Complexity in non-pharmacological caregiving activities at the end of life: an international qualitative study. *PLoS Med* 2012;9:e1001173. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22347815>.

299. Hughes T, Schumacher M, Jacobs-Lawson JM, Arnold S. Confronting death: perceptions of a good death in adults with lung cancer. *Am J Hosp Palliat Care* 2008;25:39-44. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18160544>.

300. Kehl KA. Moving toward peace: an analysis of the concept of a good death. *Am J Hosp Palliat Care* 2006;23:277-286. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17060291>.

301. Mak JM, Clinton M. Promoting a good death: an agenda for outcomes research--a review of the literature. *Nurs Ethics* 1999;6:97-106. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10358525>.

302. Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. *JAMA* 2000;284:2476-2482. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11074777>.

303. Field M, Cassel Ce, eds. *Approaching Death: Improving Care at the End of Life*. Washington, D.C: National Academy Press; 1997.

304. Guldin MB, Vedsted P, Zachariae R, et al. Complicated grief and need for professional support in family caregivers of cancer patients in palliative care: a longitudinal cohort study. *Support Care Cancer* 2011. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21892795>.

305. Kacel E, Gao X, Prigerson HG. Understanding bereavement: what every oncology practitioner should know. *J Support Oncol* 2011;9:172-180. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22024306>.

306. Zhang B, El-Jawahri A, Prigerson HG. Update on bereavement research: evidence-based guidelines for the diagnosis and treatment of complicated bereavement. *J Palliat Med* 2006;9:1188-1203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17040157>.

307. Thomas K, Hudson P, Trauer T, et al. Risk Factors for Developing Prolonged Grief During Bereavement in Family Carers of Cancer Patients in Palliative Care: A Longitudinal Study. *J Pain Symptom Manage* 2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23969327>

308. El-Jawahri A, Greer JA, Temel JS. Does palliative care improve outcomes for patients with incurable illness? A review of the evidence. *J*



Support Oncol 2011;9:87-94. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21702398>.

309. Hui D, Arthur J, Dalal S, Bruera E. Quality of the supportive and palliative oncology literature: a focused analysis on randomized controlled trials. Support Care Cancer 2012;20:1779-1785. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21935717>.

310. Gelfman LP, Du Q, Morrison RS. An update: NIH research funding for palliative medicine 2006 to 2010. J Palliat Med 2013;16:125-129. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23336358>.

311. Hui D, Glitza I, Chisholm G, et al. Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials. Cancer 2013;119:1098-1105. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/23132290>.

312. Leblanc TW, Lodato JE, Currow DC, Abernethy AP. Overcoming recruitment challenges in palliative care clinical trials. J Oncol Pract 2013;9:277-282. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/24130254>.

313. Agar M, Luckett T. Outcome measures for palliative care research. Curr Opin Support Palliat Care 2012;6:500-507. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/23080308>.

314. Davis MP, Mitchell GK. Topics in research: structuring studies in palliative care. Curr Opin Support Palliat Care 2012;6:483-489. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23123820>.

315. Kamal AH, Swetz KM, Dy S, et al. Integrating technology into palliative care research. Curr Opin Support Palliat Care 2012;6:525-532. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23080307>.

316. LeBlanc TW, Abernethy AP, Currow DC, Kutner JS. Considerations in reporting palliative care clinical trials: standardizing information reported and authorship practices. Curr Opin Support Palliat

Care 2012;6:494-499. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/23080306>.

317. Lodato JE, Aziz N, Bennett RE, et al. Achieving palliative care research efficiency through defining and benchmarking performance metrics. Curr Opin Support Palliat Care 2012;6:533-542. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/23080309>.

318. Hagen NA, Biondo PD, Brasher PM, Stiles CR. Formal feasibility studies in palliative care: why they are important and how to conduct them. J Pain Symptom Manage 2011;42:278-289. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21444184>.

319. Hartmann LC. Unrealistic expectations. J Clin Oncol 2005;23:4231-4232; discussion 4233-4234. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/15961772>.

320. Kalemkerian GP. Commentary on "Unrealistic Expectations". J Clin Oncol 2005;23:4233-4234. Available at:
<http://jco.ascopubs.org/content/23/18/4233.short>.

321. Najjar N, Davis LW, Beck-Coon K, Carney Doebbeling C. Compassion fatigue: a review of the research to date and relevance to cancer-care providers. J Health Psychol 2009;14:267-277. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/19237494>.

322. Cohen JS, Erickson JM. Ethical dilemmas and moral distress in oncology nursing practice. Clin J Oncol Nurs 2006;10:775-780. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17193943>.

323. Gaeta S, Price KJ. End-of-life issues in critically ill cancer patients. Crit Care Clin 2010;26:219-227. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/19944283>.

324. Irvin S. The experiences of the registered nurse caring for the person dying of cancer in a nursing home. Collegian 2000;7:30-34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11858309>.



325. Shanafelt T, Dyrbye L. Oncologist burnout: causes, consequences, and responses. *J Clin Oncol* 2012;30:1235-1241. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22412138>.

326. Sherman AC, Edwards D, Simonton S, Mehta P. Caregiver stress and burnout in an oncology unit. *Palliat Support Care* 2006;4:65-80. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16889325>.

327. Slocum-Gori S, Hemsworth D, Chan WW, et al. Understanding Compassion Satisfaction, Compassion Fatigue and Burnout: a survey of the hospice palliative care workforce. *Palliat Med* 2013;27:172-178. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22179596>.

328. Potter P, Deshields T, Berger JA, et al. Evaluation of a compassion fatigue resiliency program for oncology nurses. *Oncol Nurs Forum* 2013;40:180-187. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23448743>.

329. Aycock N, Boyle D. Interventions to manage compassion fatigue in oncology nursing. *Clin J Oncol Nurs* 2009;13:183-191. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19349265>.

330. Zambrano SC, Chur-Hansen A, Crawford GB. The experiences, coping mechanisms and impact of death and dying on palliative medicine specialists. *Palliat Support Care* 2013;1-8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23750857>.

331. Sanchez-Reilly S, Morrison LJ, Carey E, et al. Caring for oneself to care for others: physicians and their self-care. *J Support Oncol* 2013;11:75-81. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23967495>.